<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2164508-B1" country="EP" doc-number="2164508" kind="B1" date="20140108" family-id="39940641" file-reference-id="314651" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588263" ucid="EP-2164508-B1"><document-id><country>EP</country><doc-number>2164508</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08763515-A" is-representative="NO"><document-id mxw-id="PAPP154850455" load-source="docdb" format="epo"><country>EP</country><doc-number>08763515</doc-number><kind>A</kind><date>20080604</date><lang>EN</lang></document-id><document-id mxw-id="PAPP262097027" load-source="docdb" format="original"><country>EP</country><doc-number>08763515.7</doc-number><date>20080604</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140554731" ucid="IL-2008000757-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>IL</country><doc-number>2008000757</doc-number><kind>W</kind><date>20080604</date></document-id></priority-claim><priority-claim mxw-id="PPC140554456" ucid="US-92486607-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>92486607</doc-number><kind>P</kind><date>20070604</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20110930</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL-1620483071" load-source="docdb">A61K  35/17        20150101A I20180629RMEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325113" load-source="docdb">A61K  38/19        20060101AFI20081223BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325114" load-source="docdb">A61P  25/00        20060101ALI20081223BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325115" load-source="docdb">A61P  29/00        20060101ALI20081223BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1991294341" load-source="docdb" scheme="CPC">C07K  14/522       20130101 LI20140110BHEP        </classification-cpc><classification-cpc mxw-id="PCL1991299663" load-source="docdb" scheme="CPC">A61K  38/00        20130101 LA20140110BHEP        </classification-cpc><classification-cpc mxw-id="PCL1991300132" load-source="docdb" scheme="CPC">A61K  35/17        20130101 FI20140110BHEP        </classification-cpc><classification-cpc mxw-id="PCL1991301195" load-source="docdb" scheme="CPC">A61K  45/06        20130101 LI20140110BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369422" lang="DE" load-source="patent-office">MITTEL ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN UND ANWENDUNGSVERFAHREN DAFÜR</invention-title><invention-title mxw-id="PT132369423" lang="EN" load-source="patent-office">AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND METHODS OF USING SAME</invention-title><invention-title mxw-id="PT132369424" lang="FR" load-source="patent-office">AGENTS DESTINÉS AU TRAITEMENT DE MALADIES INFLAMMATOIRES ET LEURS PROCÉDÉS D'UTILISATION</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919541522" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>RAPPAPORT FAMILY INST FOR RES</last-name><address><country>IL</country></address></addressbook></applicant><applicant mxw-id="PPAR919508960" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919519570" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>KARIN NATHAN</last-name><address><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR919510325" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>KARIN, NATHAN</last-name></addressbook></inventor><inventor mxw-id="PPAR919022305" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>KARIN, NATHAN</last-name><address><street>9 Caspari Street</street><city>34677 Haifa</city><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR919524923" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ZOHAR YANIV</last-name><address><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR919515991" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ZOHAR, YANIV</last-name></addressbook></inventor><inventor mxw-id="PPAR919022307" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ZOHAR, YANIV</last-name><address><street>39 Havatzelet Street</street><city>26235 Kiryat-haim</city><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR919527267" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>WILDBAUM GIZI</last-name><address><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR919515715" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>WILDBAUM, GIZI</last-name></addressbook></inventor><inventor mxw-id="PPAR919022306" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>WILDBAUM, GIZI</last-name><address><street>3 Mairon Street</street><city>29036 Kiryat Yam</city><country>IL</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919022308" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Rappaport Family Institute for Research in the Medical Sciences</last-name><iid>101092967</iid><address><street>Efron Street P.O.Box 9697</street><city>31096 Haifa</city><country>IL</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919022309" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Dennemeyer &amp; Associates S.A.</last-name><iid>101219367</iid><address><street>55, rue des Bruyères</street><city>1274 Howald</city><country>LU</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="IL-2008000757-W"><document-id><country>IL</country><doc-number>2008000757</doc-number><kind>W</kind><date>20080604</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2008149354-A2"><document-id><country>WO</country><doc-number>2008149354</doc-number><kind>A2</kind><date>20081211</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549923359" load-source="docdb">AT</country><country mxw-id="DS549784161" load-source="docdb">BE</country><country mxw-id="DS549871818" load-source="docdb">BG</country><country mxw-id="DS549876373" load-source="docdb">CH</country><country mxw-id="DS549783365" load-source="docdb">CY</country><country mxw-id="DS549923360" load-source="docdb">CZ</country><country mxw-id="DS549784162" load-source="docdb">DE</country><country mxw-id="DS549783366" load-source="docdb">DK</country><country mxw-id="DS549783367" load-source="docdb">EE</country><country mxw-id="DS549891214" load-source="docdb">ES</country><country mxw-id="DS549871819" load-source="docdb">FI</country><country mxw-id="DS549868703" load-source="docdb">FR</country><country mxw-id="DS549784163" load-source="docdb">GB</country><country mxw-id="DS549783368" load-source="docdb">GR</country><country mxw-id="DS549784164" load-source="docdb">HR</country><country mxw-id="DS549923361" load-source="docdb">HU</country><country mxw-id="DS549876378" load-source="docdb">IE</country><country mxw-id="DS549783377" load-source="docdb">IS</country><country mxw-id="DS549868704" load-source="docdb">IT</country><country mxw-id="DS549783378" load-source="docdb">LI</country><country mxw-id="DS549871820" load-source="docdb">LT</country><country mxw-id="DS549800833" load-source="docdb">LU</country><country mxw-id="DS549871821" load-source="docdb">LV</country><country mxw-id="DS549871826" load-source="docdb">MC</country><country mxw-id="DS549800834" load-source="docdb">MT</country><country mxw-id="DS549923362" load-source="docdb">NL</country><country mxw-id="DS549891215" load-source="docdb">NO</country><country mxw-id="DS549876379" load-source="docdb">PL</country><country mxw-id="DS549871827" load-source="docdb">PT</country><country mxw-id="DS549923363" load-source="docdb">RO</country><country mxw-id="DS549876380" load-source="docdb">SE</country><country mxw-id="DS549868705" load-source="docdb">SI</country><country mxw-id="DS549891216" load-source="docdb">SK</country><country mxw-id="DS549800835" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960688" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">The present invention relates to the use of CXCL11 for the treatment of inflammatory diseases in general and Multiple Sclerosis in particular.</p><p id="p0002" num="0002">Chemokines constitute a family of small structurally cytokine-like, secreted proteins that regulate cell trafficking. They are produced and secreted by a wide variety of cell types in response to early inflammatory mediators, such as IL-1β or TNF-α, and in response to bacterial or viral infection. Chemokines function mainly as chemoattractants for leukocytes, recruiting monocytes, neutrophils and other effector cells from the blood to sites of infection or damage. They can be released by many different cell types (e.g. macrophages) and can mediate a range of pro-inflammatory effects on leukocytes, such as triggering of chemotaxis, degranulation, synthesis of lipid mediators, and integrin activation.</p><p id="p0003" num="0003">Chemokines can be subdivided into four classes, the C, C-C, C-X-C and C-X3-C chemokines, depending on the number and arrangement of the conserved amino-terminal cysteine motifs, where "X" is a nonconserved amino acid residue. The interaction of these soluble proteins with their specific receptors, which belong to the superfamily of seven-transmembrane domain G-protein-coupled receptors (GPCRs), mediate their biological effects resulting in, among other responses, rapid increase in intracellular calcium concentration, changes in cell shape, increased expression of cellular adhesion molecules, degranulation, and promotion of cell migration.</p><p id="p0004" num="0004">The chemokine receptor CXCR3, also referred to as G protein-coupled receptor 9 (GPR9) and CD 183, is predominantly expressed on inflammatory effector T cells, including Th1 cells [<nplcit id="ncit0001" npl-type="s"><text>Qin et al., J Clin Invest (1998) 101:746-54</text></nplcit>; <nplcit id="ncit0002" npl-type="s"><text>Sallusto et al., J Exp Med (1998) 187:875-83</text></nplcit>] as well as the newly defined IL-17 producing Th<sub>17</sub> cells [<nplcit id="ncit0003" npl-type="s"><text>Nakae et al., J Leukoc Biol (2007) 81:1258-68</text></nplcit>], but is also expressed on other lymphocytes, including B cells and NK cells [Sallusto et al., supra]. CXCR3 is highly induced following cell activation. Three chemokine ligands compete for binding to this receptor: CXCL9 (MIG), CXCL10 (IP-10) and CXCL11 (I-TAC) [<nplcit id="ncit0004" npl-type="s"><text>Colvin et al., J Biol Chem (2004) 279:30219-27</text></nplcit>]. These ligands bind different epitopes on CXCR3, yet CXCL11 binds CXCR3 with higher affinity than CXCL9 and CXCL10 [Cole et al., supra; <nplcit id="ncit0005" npl-type="s"><text>Tensen et al., J. Invest. Derm.<!-- EPO <DP n="2"> --> (1999) 112:716-722</text></nplcit>]. CXCL11 may antagonize the function of the other two CXCR3 ligands since it rapidly leads to receptor internalization, which thus becomes inaccessible to the other CXCR3 ligands [Colvin et al., supra].</p><p id="p0005" num="0005">Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS). MS and its animal model, experimental autoimmune encephalomyelitis (EAE), are believed to result from autoimmune mediated activated immune cells, such as T- and B-lymphocytes as well as macrophages and microglia, and is considered to be an inflammatory neurodegenerative disease. Pathologically, MS is characterized by perivenous infiltration of lymphocytes and macrophages into the CNS parenchyma, resulting in demyelinative lesions termed plaques. These plaques, which are the hallmark of MS, are associated with oligodendrocytes death, axonal damage and neuronal loss. The inflammatory cell recruitment from the vascular bed to the perivascular space, and from there on to the CNS parenchyma, is the result of a multi-step process, which is orchestrated in part by chemokines.</p><p id="p0006" num="0006">CXCR3 has been previously implicated in the pathogenesis of MS [<nplcit id="ncit0006" npl-type="s"><text>Sorensen et al., J Clin Invest. (1999) 103(6):807-15</text></nplcit>]. CXCR3 has been shown to be expressed on lymphocytic cells in virtually every perivascular inflammatory infiltrate in active MS lesions [Sorensen et al., supra]. Furthermore, elevated levels of the two CXCR3 ligands, CXCL9 and CXCL10, were found in the cerebrospinal fluid (CSF) of subjects during MS attacks which are probably accountable for the chemoattraction of CXCR3 expressing cells (e.g. CD4<sup>+</sup> T cells) from the blood circulation into the site of inflammation [<nplcit id="ncit0007" npl-type="s"><text>Balashov et al. Proc Natl Acad Sci USA (1999) 96:6873-8</text></nplcit>; Sorensen et al., supra]. Additionally, in EAE induced mice, administration of anti-CXCL10 antibodies decreased clinical and histological disease incidence, severity, as well as infiltration of mononuclear cells and The cells into the CNS [<nplcit id="ncit0008" npl-type="s"><text>Fife et al, J Immunol (2001) 166:7617-24</text></nplcit>]. Taken together, these findings provide strong cumulative evidence supporting a pivotal role for CXCR3/CXCL10/CXCL9 axis in T cell recruitment to the brain in MS. Yet the role the CXCR3/CXCL11 axis plays in MS is still vague.</p><p id="p0007" num="0007">There is substantial evidence to support the hypothesis that CXCL11 is involved in MS pathogenesis. For example, Hamilton et al. have shown elevated levels of murine I-TAC mRNA in CNS of EAE induced mice [<nplcit id="ncit0009" npl-type="s"><text>Hamilton et al., Scand J Immunol. (2002) 55(2):171-7</text></nplcit>].<!-- EPO <DP n="3"> --></p><p id="p0008" num="0008">Lazzeri and Romagnani have proposed the chemokine CXCL11 as a possible therapeutic target in multiple sclerosis, however, they in fact teach away from using CXCL11 for MS treatment as they propose treatment of MS by using drugs that block CXCL11 activity [<nplcit id="ncit0010" npl-type="s"><text>Lazzeri E. and Romagnani P., Curr Drug Targets Immune Endocr Metabol Disord. (2005) 5(1):109-18</text></nplcit>].</p><p id="p0009" num="0009">Clark-Lewis et al. constructed a potent antagonist for the CXCR3 receptor which enabled them to explore the structure-function relationship of CXCR3 with its ligands, in particular I-TAC. The antagonist was obtained by NH(2)-terminal truncation of I-TAC. This molecule (I-TAC (4-73)), lacked the first three residues and was shown to comprise no agonistic activity. Instead it was shown to compete with I-TAC for the binding to CXCR3-bearing cells, inhibiting cell migration and inhibiting calcium changes in CXCR3 expressing cells in response to stimulation with CXCR3 chemokines. The I-TAC antagonist was not contemplated for therapeutics [<nplcit id="ncit0011" npl-type="s"><text>Clark-Lewis et al., J Biol Chem. (2003) 278(1):289-95</text></nplcit>].</p><p id="p0010" num="0010"><patcit id="pcit0001" dnum="US6869606B"><text>U.S. Pat. No. 6,869,606</text></patcit> discloses biotinylated-I-TAC complexes which maintain their functionality (e.g., binding to CXCR3 and inducing chemotaxis). <patcit id="pcit0002" dnum="US6869606B"><text>U.S. Pat. No. 6,869,606</text></patcit> does not mention Multiple Sclerosis as a potential target disease for such complexes.</p><p id="p0011" num="0011"><patcit id="pcit0003" dnum="US20060257359A"><text>U.S. Publication No. 20060257359</text></patcit> discloses means of modulating phenotypes of macrophage related cells for the treatment of diseases, such as Multiple Sclerosis. <patcit id="pcit0004" dnum="US20060257359A"><text>U.S. Publication No. 20060257359</text></patcit> teaches that modulation of the cellular phenotype may be accomplished by introducing effectors (e.g., proteins, antibodies or RNA molecules) to macrophage related cells thereby altering gene expression and cell phenotype (e.g., secretion of cytokines or cell migration). Amongst a long list of potential effectors, I-TAC is specified therein. <patcit id="pcit0005" dnum="US20060257359A"><text>U.S. Publication No. 20060257359</text></patcit> describes treatment of a great number of autoimmune diseases yet it does not specify which diseases may be alleviated by up-regulation or down-regulation of I-TAC. In addition, <patcit id="pcit0006" dnum="US20060257359A"><text>U.S. Publication No. 20060257359</text></patcit> does not provide any experimental support to indicate treatment of MS with I-TAC.</p><p id="p0012" num="0012"><patcit id="pcit0007" dnum="WO06125077A"><text>PCT Publication No. WO06125077</text></patcit> discloses a non-natural CXCR3 polypeptide receptor ligand wherein the N-loop domain is from I-TAC for treatment of fibrotic disorders, angiogenic disorders and cancer. Treatment of MS was not contemplated.</p><p id="p0013" num="0013"><patcit id="pcit0008" dnum="WO05016241A"><text>PCT Publication No. WO05016241</text></patcit> discloses a synthetic CXCR3 polypeptide ligand for treating fibrotic disorders, angiogenic disorders, cancer and bacterial infections.<!-- EPO <DP n="4"> --> This invention describes the use of I-TAC consensus sequence (amino acid residues which occur in I-TAC) which include or lack a signaling sequence. Thus, such CXCR3 polypeptides may function as agonist or antagonists of CXCR3. Treatment of MS was not contemplated.</p><p id="p0014" num="0014">There is thus a widely recognized need for, and it would be highly advantageous to have CXCL11 polypeptides that can be used in the treatment of Multiple Sclerosis.</p><heading id="h0001"><u>SUMMARY OF THE INVENTION</u></heading><p id="p0015" num="0015">According to one aspect of the present invention there is provided a method of treating an autoimmune disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of CXCL11, thereby treating the autoimmune disease in the subject.</p><p id="p0016" num="0016">According to another aspect of the present invention there is provided a method of treating Multiple Sclerosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of CXCL11, thereby treating Multiple Sclerosis in the subject.</p><p id="p0017" num="0017">According to yet another aspect of the present invention there is provided a use of CXCL11 for the manufacture of a medicament identified for treating an autoimmune disease.</p><p id="p0018" num="0018">According to yet another aspect of the present invention there is provided a method of treating an autoimmune disease in a subject in need thereof, the method comprising ex vivo contacting T cells with CXCL11 under conditions which result in generation of regulatory T cells and administering the regulatory T cells to the subject, thereby treating the autoimmune disease in the subject.</p><p id="p0019" num="0019">According to yet another aspect of the present invention there is provided a method of treating Multiple Sclerosis in a subject in need thereof, the method comprising ex vivo contacting T cells with CXCL11 under conditions which result in generation of regulatory T cells and administering the regulatory T cells to the subject, thereby treating Multiple Sclerosis in the subject.</p><p id="p0020" num="0020">According to yet another aspect of the present invention there is provided a use of T cells ex vivo cultured with CXCL11 for the manufacture of a medicament identified for treating an autoimmune disease.<!-- EPO <DP n="5"> --></p><p id="p0021" num="0021">According to further features in preferred embodiments of the invention described below the the T cells are obtained from the subject.</p><p id="p0022" num="0022">According to still further features in the described preferred embodiments the T cells are obtained from a donor.</p><p id="p0023" num="0023">According to still further features in the described preferred embodiments the donor is allogeneic with respect to the subject.</p><p id="p0024" num="0024">According to still further features in the described preferred embodiments the donor is syngeneic with respect to the subject.</p><p id="p0025" num="0025">According to still further features in the described preferred embodiments the T cells are CD4+ T cells.</p><p id="p0026" num="0026">According to still further features in the described preferred embodiments the regulatory T cells are specifically selected prior to administering to the subject.</p><p id="p0027" num="0027">According to still further features in the described preferred embodiments the conditions which result in generation of regulatory T cells further comprise stimulation with an antigen.</p><p id="p0028" num="0028">According to still further features in the described preferred embodiments the antigen is anti-CD3ε mAb.</p><p id="p0029" num="0029">According to still further features in the described preferred embodiments the antigen is anti-CD28 mAb.</p><p id="p0030" num="0030">According to still further features in the described preferred embodiments the regulatory T cells secrete IL-10.</p><p id="p0031" num="0031">According to still further features in the described preferred embodiments the regulatory T cells secrete IL-4.</p><p id="p0032" num="0032">According to still another aspect of the present invention there is provided an article of manufacture comprising CXCL11 and an anti-Multiple Sclerosis agent being packaged in a packaging material and identified in print, in or on the packaging material for use in the treatment of Multiple Sclerosis.</p><p id="p0033" num="0033">According to an additional aspect of the present invention there is provided an isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 6.</p><p id="p0034" num="0034">According to yet an additional aspect of the present invention there is provided a pharmaceutical composition comprising as an active ingredient the isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 6 and a pharmaceutically acceptable carrier.<!-- EPO <DP n="6"> --></p><p id="p0035" num="0035">According to still an additional aspect of the present invention there is provided a use of the isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 6, for the manufacture of a medicament identified for treating an inflammatory disease.</p><p id="p0036" num="0036">According to still further features in the described preferred embodiments, the CXCL11 is capable of up-regulating secretion of IL-10 and/or IL-4 from macrophages and T cells.</p><p id="p0037" num="0037">According to still further features in the described preferred embodiments the CXCL11 is capable of down-regulating secretion of a cytokine from macrophages and T cells, wherein the cytokine is selected from the group consisting of TNF-α, IFN-γ, IL-2 and IL-12.</p><p id="p0038" num="0038">According to still further features in the described preferred embodiments the CXCL11 is capable of CXCR3 receptor down-regulation.</p><p id="p0039" num="0039">According to still further features in the described preferred embodiments the inflammatory disease is an autoimmune disease.</p><p id="p0040" num="0040">According to still further features in the described preferred embodiments the autoimmune disease is selected from the group consisting of rheumatoid arthritis, rheumatoid spondylitis, osteroarthritis, gouty arthritis, arthritic conditions, inflamed joints, eczema, inflammatory skin conditions, inflammatory eye conditions, conjunctivitis, pyresis, tissue necrosis resulting from inflammation, tissue rejection following transplant surgery, Crohn's disease and ulcerative colitis, airway inflammation, asthma, bronchitis, systemic lupus erythematosis, multiple sclerosis, myasthenia gravis, progressive systemic sclerosis, atopic dermatitis, hyperimmunoglobin E, hepatitis B antigen negative chronic active hepatitis, Hashimoto's thyroiditis, familial Mediterranean fever, Grave's disease, autoimmune haemolytic anemia, primary biliary cirrhosis, inflammatory bowel disease, viral infections, HIV infections and AIDS.</p><p id="p0041" num="0041">According to still further features in the described preferred embodiments the autoimmune disease is Multiple Sclerosis.</p><p id="p0042" num="0042">According to still further features in the described preferred embodiments, an amino acid sequence of the CXCL11 is attached to a heterologous amino acid sequence.</p><p id="p0043" num="0043">According to still further features in the described preferred embodiments the method further comprises administering to the subject an additional anti-Multiple Sclerosis agent.<!-- EPO <DP n="7"> --></p><p id="p0044" num="0044">According to still further features in the described preferred embodiments the anti-Multiple Sclerosis agent is selected from the group consisting of Interferon Beta 1a, Interferon Beta 1b, Glatiramer Acetate, Mitoxantrone, MethylPrednisolone, Prednisone, Prednisolone, Dexamethasone, Adreno-corticotrophic Hormone (ACTH) and Corticotropin.</p><p id="p0045" num="0045">The present invention successfully addresses the shortcomings of the presently known configurations by providing a novel means of treating inflammatory diseases.</p><p id="p0046" num="0046">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.</p><heading id="h0002"><u>BRIEF DESCRIPTION OF THE DRAWINGS</u></heading><p id="p0047" num="0047">The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.</p><p id="p0048" num="0048">In the drawings:
<ul><li><figref idrefs="f0001">FIGS. 1A-B</figref> are bar graphs depicting specificity of anti-CXCL9, anti-CXCL10 and anti-CXCL11 antibodies. <figref idrefs="f0001">Figure 1A</figref> shows selectivity of binding of each of the DNA-vaccination based antibodies to each of the three CXCR3 ligands; CXCL9, CXCL10 and CXCL11 as detected by ELISA. Results of triplicates are shown as mean OD (450 nm) ± SE. <figref idrefs="f0001">Figure 1B</figref> shows neutralization of chemotaxis by each of the DNA-vaccination based<!-- EPO <DP n="8"> --> antibodies using a Trans-well migration assay. The ability of each antibody to inhibit the chemokine-induced migration of CXCR3+ cells (MOG specific CD4+ Th1 line constructed by the present inventor) by each chemokine was measured. Results of triplicate measurements were analyzed by flow cytometry and are shown as mean relative cell number ± SE.</li><li><figref idrefs="f0002">FIG. 2</figref> is a graph depicting the experimental autoimmune encephalomyelitis (EAE) score of mice following administration of anti-CXCL9, anti-CXCL10 or anti-CXCL11 antibodies. The graph shows the results of a representative experiment (1 out of 3 with similar observations) in which, just after the onset of disease (day 11), EAE induced mice were separated into five equally sick groups and administered (on days 11, 13, 15 and 17) either with DNA vaccination based neutralizing antibodies against CXCL9 (close squares), CXCL10 (open triangles) or CXCL11 (close triangles). The remaining two groups of EAE mice were administered with purified antibodies from rats previously injected with an empty vector alone (open circles) or remained untreated (open squares). An observer blind to the experimental protocol then monitored the development and progression of disease. Results are shown as mean maximal score ± SE.</li><li><figref idrefs="f0002">FIG. 3</figref> is a graph depicting CXCL11-IgG and CXCLI0-IgG fusion proteins preserving their functional properties. The graph shows the ability of CXCL11-IgG and CXCL10-IgG fusion proteins to attract CXCR3+ T cells in a trans-well system and the competence of anti CXCL11 and anti CXCL10 neutralizing antibodies (R&amp;D Systems) to selectively inhibit the chemokine-induced migration of each chemokine. Results of triplicate measurements were analyzed by flow cytometry and are shown as mean relative cell number ± SE.</li><li><figref idrefs="f0003">FIG. 4</figref> is a graph depicting the EAE score of mice following administration of the fusion proteins CXCL11-IgG or CXCL10-IgG. The graph shows the results of a representative experiment (1 out of 4 with similar observations) in which, just after the onset of disease (day 11), EAE induced mice were separated into five equally sick groups and administered (on days 11, 13, 15 and 17) with either CXCL10-IgG (open triangles) or CXCL11-IgG (close triangles). The remaining groups were administered with purified β-actin-IgG (close squares), isotype matched IgG1 (open circles), or remained untreated (open squares). An observer blind to the experimental protocol then monitored the development and progression of disease. Results are shown as mean maximal score ± SE.<!-- EPO <DP n="9"> --></li><li><figref idrefs="f0004">FIGs. 5A-F</figref> are bar graphs depicting ex-vivo production of cytokines in primary T cell cultures in response to the target antigen (MOG<sub>35-55</sub>) Primary T cells were collected from the cervical lymph nodes (CLN) of EAE induced mice at the peak of disease (on day15). T cells were stimulated with the target antigen MOG<sub>35-53</sub> peptide and were cultured in the presence of CXCL10-IgG, CXCL11-IgG or PBS or hIgG control antibody for 72 hours. Supernatants were collected and analyzed by ELISA. <figref idrefs="f0004">Figure 5A</figref> shows TNF-α secretion; <figref idrefs="f0004">Figure 5B</figref> shows IFN-γ secretion; <figref idrefs="f0004">Figure 5C</figref> shows IL-12 secretion; <figref idrefs="f0004">Figure 5D</figref> shows IL-2 secretion; <figref idrefs="f0004">Figure 5E</figref> shows IL-4 secretion; and <figref idrefs="f0004">Figure 5F</figref> shows IL-10 secretion. Results of triplicates are shown as mean cytokine level ± SE.</li><li><figref idrefs="f0005">FIG. 6</figref> is a graph depicting the EAE score of mice following transfer of T cells from EAE treated or untreated donors. Primary spleen cells from CXCL11-IgG treated or untreated EAE induced donor mice were cultured with their MOG<sub>35-55</sub> target antigen and transferred to EAE induced recipient mice, just after the onset of disease as follows: cells from donors treated with CXCL11IgG (close squares); cells from control EAE induced mice (open circles); and mice not subjected to donor T cells (open squares). An observer blind to the experimental protocol then monitored the development and progression of disease. Results presented are representative results of one out of two experiments with very similar observations Results are shown as mean maximal score of six mice per group ±SE.</li><li><figref idrefs="f0006">FIGs. 7A-E</figref> are bar graphs depicting ex-vivo production of cytokines in primary T cell cultures in response to the target antigen (MOG<sub>35-55</sub>) supplemented or not supplemented with CXCL11-IgG. Cytokine production was determined by ELISA as follows: <figref idrefs="f0006">Figure 7A</figref> shows IL-10 secretion; <figref idrefs="f0006">Figure 7B</figref> shows IL-4 secretion; <figref idrefs="f0006">Figure 7C</figref> shows IFN-γ secretion; <figref idrefs="f0006">Figure 7D</figref> shows TNF-α secretion; and <figref idrefs="f0006">Figure 7E</figref> shows TGF-β secretion. Results of triplicates are shown as mean cytokine level ± SE.</li><li><figref idrefs="f0006">FIGs. 8A-B</figref> are histograms of FACS analysis depicting IL-10 producing T cells. Flow cytometry analysis was gated on CD4+ and on IL-10 (horizontal axis). <figref idrefs="f0006">Figure 8A</figref> shows control MOG<sub>35-55</sub> activated spleen cells. <figref idrefs="f0006">Figure 8B</figref> shows MOG<sub>35-55</sub> activated spleen cells that were co-cultured with CXCL11-IgG.</li><li><figref idrefs="f0007">FIG. 9</figref> is a graph depicting the EAE score of mice following transfer of primary T cells from cultures previously cultured with the target antigen (MOG<sub>35-55</sub>) supplemented or not supplemented with CXCL11-IgG. Primary spleen cells were transferred to EAE induced recipient mice, just after the onset of disease (on day 11) as follows: recipients of<!-- EPO <DP n="10"> --> cells previously cultured with CXCL11IgG (close squares), recipients of cells previously cultured only with MOG<sub>35-55</sub> (close circles), no treatment (open squares), recipients of cells that following the administration of T cells previously cultured with CXCL11IgG, were administered with anti IL-10 neutralizing antibodies (open circles, * this group was monitored for only 10 days to avoid production of xerographic antibodies). An observer blind to the experimental protocol then monitored the development and progression of disease. The results presented summarize one of two independent experiments with the same pattern of data. Results are shown as mean maximal score of six mice per group ± SE.</li><li><figref idrefs="f0008 f0009">FIGs. 10A-K</figref> are bar graphs depicting repolarization of effector and naïve T cells in response to CXCL11 stimulation in vitro. <figref idrefs="f0008">Figures 10A-F</figref> show ex-vivo cytokines production by primary T cell cultures in response to the target antigen (MOG<sub>35-55</sub>) Primary T cells were isolated from EAE induced mice (on day 9) and were further cultured for 72 hours with MOG35-55 (50 µg/ml) in the presence of either rmCXCL10 or rmCXCL11 (50 ng/ml). TNF-α (<figref idrefs="f0008">Figure 10A</figref>), IFN-γ (<figref idrefs="f0008">Figure 10B</figref>), IL-12 (<figref idrefs="f0008">Figure 10C</figref>), IL-2 (<figref idrefs="f0008">Figure 10D</figref>), IL-4 (<figref idrefs="f0008">Figure 10E</figref>) and IL-10 (<figref idrefs="f0008">Figure 10F</figref>) cytokine levels in the culture media were determined by ELISA according to the manufacturer's protocol. Results are shown as mean level ± SE; <figref idrefs="f0009">Figures 10G-K</figref> show ex-vivo cytokine production by naïve CD4+ T cells. Naïve CD4+ T cells were purified from mice spleens using magnetic beads and were stimulated (300,000 cell/ml) for 48 hours with immobilized anti-CD3ε mAb and soluble anti-CD28 mAb in the presence of either rmCXCL10 or rmCXCL11 (50 ng/ml). TNF-α (<figref idrefs="f0009">Figure 10G</figref>), IFN-γ (<figref idrefs="f0009">Figure 10H</figref>), IL-2 (<figref idrefs="f0009">Figure 10I</figref>), IL-4 (<figref idrefs="f0009">Figure 10J</figref>) and IL-10 (<figref idrefs="f0009">Figure 10K</figref>) cytokine levels in the culture media were determined by ELISA according to manufacturer's protocol. Results are shown as mean level ± SE.</li><li><figref idrefs="f0010">FIG. 11</figref> is a bar graph showing that CXCL11 activity is CXCR3 mediated. Human CD4+ T cells were purified from peripheral blood mononuclear cells using anti-CD4 magnetic beads and were stimulated (300,000 cell/ml) for 48 hours with anti-CD3ε mAb in the presence of either rhCXCL10 or rhCXCL11 (10 ng/ml). Some of the cultures were further supplemented with the neutralizing anti-CXCR3 antibody (0.5 µg/ml). IL-10 levels were determined by ELISA according to manufacturer's protocol. IL-10 levels are shown as mean levels ± SE.</li></ul><!-- EPO <DP n="11"> --></p><heading id="h0003"><u>DESCRIPTION OF THE PREFERRED EMBODIMENTS</u></heading><p id="p0049" num="0049">The present invention is of methods of treating autoimmune disorders, such as Multiple Sclerosis using CXCL11 and pharmaceutical compositions comprising same.</p><p id="p0050" num="0050">The principles and operation of the methods and compositions according to the present invention may be better understood with reference to the drawings and accompanying descriptions.</p><p id="p0051" num="0051">Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.</p><p id="p0052" num="0052">Traditionally chemokines has been looked at mostly as pro-inflammatory mediators that attract inflammatory leucocytes, particularly effector T cells and activated monocytes to sites of inflammation, and therefore many of them and their seven-transmembrane, G protein-coupled receptors have been major targets for therapy of inflammatory autoimmune diseases.</p><p id="p0053" num="0053">CXCL9, CXCL10 and CXCL11 are all potent chemokines that mediate their activities by binding to a common receptor named CXCR3. Whilst there is strong cumulative evidence suggesting that both CXCL9 and CXCL10 are pro-inflammatory mediators and that the CXCR3/CXCL10/CXCL9 axis plays a pivotal role in T cell recruitment to the brain in Multiple Sclerosis (MS), little is known about the function of CXCL11 in general and the role it plays in MS in particular.</p><p id="p0054" num="0054">Whilst reducing the present invention to practice, the present inventors have unexpectedly discovered that CXCL11, unlike its counterpart CXCR3 activators, may act as an anti-inflammatory mediator and accordingly it can be used to as an agent for the treatment of autoimmune disorders.</p><p id="p0055" num="0055">Specifically, the present inventors have shown that antibody-mediated blockage of CXCL11 aggravates experimental autoimmune encephalomyelitis (EAE) - an experimentally induced autoimmune disease of the CNS, which serves as an experimental animal model for Multiple sclerosis. This is in sharp contrast to CXCL10 or CXCL9, where neutralization thereof was shown to suppress EAE (<figref idrefs="f0002">Figure 2</figref>).<!-- EPO <DP n="12"> --></p><p id="p0056" num="0056">Using a CXCL11-Ig fusion protein, the present inventors tested CXCL11 for its competence to suppress ongoing EAE and showed that it was capable of suppressing disease severity (<figref idrefs="f0003">Figure 4</figref>). In contrast, administration of CXCL10-IgG to EAE induced mice during an ongoing disease significantly aggravated its severity. Successful therapy with CXCL11-IgG led to a significant reduction in secretion of pro-inflammatory mediators TNF-α, IFN-γ and IL-12 (<figref idrefs="f0004">Figures 5A-D</figref>) and an elevated production of the anti-inflammatory mediators IL-4 and IL-10 (<figref idrefs="f0004">Figures 5E-F</figref>).</p><p id="p0057" num="0057">Thus, according to one aspect of the present invention, there is provided a method of treating an autoimmune disease in a subject in need thereof. The method comprises administering to the subject a therapeutically effective amount of CXCL11.</p><p id="p0058" num="0058">As used herein the term "treating" refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of the inflammatory disease.</p><p id="p0059" num="0059">Herein, the phrase "autoimmune disease" refers to a disease resulting from a disordered immune reaction (e.g., antibody production) generated against components of one's own body (i.e. autoantigens). The immune system of the subject then activates an inflammatory cascade aimed at cells and tissues presenting those specific self antigens. The destruction of the antigen, tissue, cell type, or organ attacked by the individual's own immune system gives rise to the symptoms of the disease.</p><p id="p0060" num="0060">According to a preferred embodiment of the present invention, the autoimmune disease is Multiple Sclerosis, the inflammatory, demyelinating disease of the central nervous system (CNS) which is typically characterized by various symptoms of neurological dysfunction. Any type of Multiple Sclerosis may be treated according to the teachings of the present invention including relapsing-remitting, secondary progressive, primary progressive, progressive relapsing and special cases of MS with non-standard behavior (also referred to as borderline forms of MS), such as for example without limitation, Neuromyelitis optica (NMO), Balo concentric sclerosis, Schilder disease, Marburg multiple sclerosis, acute disseminated encephalomyelitis (ADEM) and autoimmune variants of peripheral neuropathies. The disease may be treated at any stage.</p><p id="p0061" num="0061">It will be appreciated that the CXCL11 of the present invention may also be used to treat other inflammatory diseases.</p><p id="p0062" num="0062">The phrase "inflammatory disease", as used herein, refers to any disease or disorder which includes a component of inflammation, which is imperative to disease onset or<!-- EPO <DP n="13"> --> progression. The inflammatory disease may be a chronic or a relapsing remitting disease. Other examples of autoimmune and other inflammatory diseases are detailed herein below.</p><p id="p0063" num="0063">The phrase "subject in need thereof' as used herein, typically refers to a human subject. Typically, the subject has been diagnosed with the inflammatory disease. The subject may or may not have received treatment for the inflammatory disease.</p><p id="p0064" num="0064">As used herein the term "CXCL11" (also referred to herein as ITAC) refers to at least an active portion of a mammalian (e.g., human) C-X-C chemokine polypeptide having at least one functional property specific to CXCL11 and not to the other CXCR3 ligands (i.e. CXCL9 and CXCL10). Accordingly, the CXCL11 of the present invention may comprise the ability to induce internalization of the CXCR3 receptor, may reduce secretion of pro-inflammatory mediators such as TNF-α, IFN-γ and IL-12 or increase production of anti-inflammatory mediators such as IL-4 and IL-10 from T cells or macrophages. Preferably, the CXCL11 of the present invention comprises all the above functional properties. According to one embodiment, the CXCL11 of the present invention is capable of suppressing on-going MS as illustrated in <figref idrefs="f0003">Figure 4</figref> (see the Examples section which follows). Examples of CXCL11 amino acid sequences are set forth in GenBank Accession Nos. AAH05292 or EAX05774. Any CXCL11 known in the art can be used in accordance with the teachings of the present invention. For example, recombinant human CXCL11 is available from ProSpec-Tany TechnoGene Ltd, Catalog No. CHM-334, from Cell Sciences and from Biovision.</p><p id="p0065" num="0065">According to a particularly preferred embodiment of the present invention, CXCL 11 is attached to a heterologous amino acid sequence.</p><p id="p0066" num="0066">As used herein the phrase "heterologous amino acid sequence" refers to an amino acid sequence which does not endogenously form a part of the CXCL11 amino acid sequence. Preferably, the heterologous amino acid sequence does not down-regulate the biological activity (e.g. anti-MS activity) of the CXCL11 polypeptide.</p><p id="p0067" num="0067">The heterologous amino acid sequence may thus serve to ensure stability of the CXCL11 of the present invention without compromising its activity. For example, the heterologous polypeptide may increase the half-life of the CXCL11 chimeric molecule in the serum. Alternatively, the heterologous amino acid sequence may aid in the isolation of a recombinant CXCL11 as further described herein below. Examples of heterologous amino acid sequences that may be used in accordance with the teachings of the present invention include, but are not limited to, immunoglobulin, galactosidase, glucuronidase,<!-- EPO <DP n="14"> --> glutathione-S-transferase (GST), carboxy terminal peptide (CTP) from chorionic gonadotrophin (CGβ) and chloramphenicol acetyltransferase (CAT) [see for example Suzuki et al., supra; and <patcit id="pcit0009" dnum="US20030171551A"><text>U.S. Publication No. 20030171551</text></patcit>].</p><p id="p0068" num="0068">The exact site at which fusion (conjugation) between the heterologous amino acid sequence and the CXCL11 amino acid sequence is not critical. Generally the heterologous amino acid sequence is localized at the amino- or carboxyl- terminus (n-ter or c-ter, respectively) of the CXCL11 polypeptide of the present invention. Particular sites are well known in the art and may be selected in order to optimize the biological activity, secretion or binding characteristics of the chimeric molecules of this aspect of the present invention.</p><p id="p0069" num="0069">The heterologous amino acid sequence may be attached to the CXCL11 amino acid sequence by any of peptide or non-peptide bond. Attachment of the CXCL11 amino acid sequence to the heterologous amino acid sequence may be effected by direct covalent bonding (peptide bond or a substituted peptide bond) or indirect binding such as by the use of a linker having functional groups. Functional groups include, without limitation, a free carboxylic acid (C(=O)OH), a free amino group (NH<sub>2</sub>), an ester group (C(=O)OR, where R is alkyl, cycloalkyl or aryl), an acyl halide group (C(=O)A, where A is fluoride, chloride, bromide or iodide), a halide (fluoride, chloride, bromide or iodide), a hydroxyl group (OH), a thiol group (SH), a nitrile group (C≡N), a free C-carbamic group (NR"-C(=O)-OR', where each of R' and R" is independently hydrogen, alkyl, cycloalkyl or aryl).</p><p id="p0070" num="0070">An example of a heterologous amino acid sequence which may be used in accordance with this aspect of the present invention is an immunoglobulin amino acid sequence, such as the hinge and Fc regions of an immunoglobulin heavy domain (see <patcit id="pcit0010" dnum="US6777196B"><text>U.S. Pat. No. 6,777,196</text></patcit>). The immunoglobulin moiety in the chimeras of this aspect of the present invention may be obtained from IgG1, IgG2, IgG3 or IgG4 subtypes, IgA, IgE, IgD or IgM, as further discussed hereinbelow. An exemplary human CXCL11 polypeptide linked to an IgG 1 moiety is set forth in SEQ ID NO: 6.</p><p id="p0071" num="0071">Chimeras constructed from a receptor sequence linked to an appropriate immunoglobulin constant domain sequence (immunoadhesins) are known in the art. Immunoadhesins reported in the literature include fusions of the T cell receptor [<nplcit id="ncit0012" npl-type="s"><text>Gascoigne et al., Proc. Natl.Acad. Sci. USA, 84: 2936-2940 (1987</text></nplcit>)]; CD4 [<nplcit id="ncit0013" npl-type="s"><text>Capon et al., Nature 337: 525-531 (1989</text></nplcit>); <nplcit id="ncit0014" npl-type="s"><text>Traunecker et al., Nature, 339: 68-70 (1989</text></nplcit>); <nplcit id="ncit0015" npl-type="s"><text>Zettmeissl et al., DNA Cell Biol. USA, 9: 347-353 (1990</text></nplcit>); <nplcit id="ncit0016" npl-type="s"><text>Byrn et al., Nature, 344: 667-670 (1990</text></nplcit>)]; L-selectin (homing receptor) [(<nplcit id="ncit0017" npl-type="s"><text>Watson et al., J. Cell. Biol., 110:2221-2229 (1990</text></nplcit>); <nplcit id="ncit0018" npl-type="s"><text>Watson et al.,<!-- EPO <DP n="15"> --> Nature, 349: 164-167 (1991</text></nplcit>)]; CD44 [<nplcit id="ncit0019" npl-type="s"><text>Aruffo et al., Cell, 61: 1303-1313 (1990</text></nplcit>)]; CD28 and B7 (<nplcit id="ncit0020" npl-type="s"><text>Linsley et al., J. Exp. Med., 173: 721-730(1991</text></nplcit>)]; CTLA-4 [<nplcit id="ncit0021" npl-type="s"><text>Lisley et al., J. Exp. Med. 174: 561-569 (1991</text></nplcit>)]; CD22 [<nplcit id="ncit0022" npl-type="s"><text>Stamenkovic et al., Cell, 66:1133-1144 (1991</text></nplcit>)]; TNF receptor [<nplcit id="ncit0023" npl-type="s"><text>Ashkenazi et al., Proc. Natl. Acad. Sci. USA, 88: 10535-10539 (1991</text></nplcit>);<nplcit id="ncit0024" npl-type="s"><text> Lesslauer et al., Eur. J. Immunol., 27: 2883-2886 (1991</text></nplcit>); <nplcit id="ncit0025" npl-type="s"><text>Peppel et al., J. Exp. Med., 174:1483-1489 (1991</text></nplcit>)]; NP receptors [<nplcit id="ncit0026" npl-type="s"><text>Bennett et al., J. Biol. Chem. 266:23060-23067 (1991</text></nplcit>)]; and IgE receptor α [<nplcit id="ncit0027" npl-type="s"><text>Ridgway et al., J. Cell. Biol., 1 15: abstr. 1448 (1991</text></nplcit>)].</p><p id="p0072" num="0072">Typically, in such fusions the chimeric molecule will retain at least functionally active hinge and CH2 and CH3 domains of the constant region of an immunoglobulin heavy chain. Fusions can also be generated to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the CH1 of the heavy chain or the corresponding region of the light chain.</p><p id="p0073" num="0073">Though it may be possible to conjugate the entire heavy chain constant region to the CXCL11 amino acid sequence of the present invention, it is preferable to fuse shorter sequences. For example, a sequence beginning at the hinge region upstream of the papain cleavage site, which defines IgG Fc chemically; residue 216, taking the first residue of heavy chain constant region to be 114, or analogous sites of other immunoglobulins, may be used in the fusion. In a particularly preferred embodiment, the CXCL11 amino acid sequence is fused to the hinge region and CH2 and CH3, or to the CH1, hinge, CH2 and CH3 domains of an IgG1, IgG2, or IgG3 heavy chain (see <patcit id="pcit0011" dnum="US6777196B"><text>U.S. Pat. No. 6,777,196</text></patcit>).</p><p id="p0074" num="0074">As mentioned, the immunoglobulin sequences used in the construction of the chimeric molecules of this aspect of the present invention may be from an IgG immunoglobulin heavy chain constant domain. According to one embodiment of the present invention, the IgG immunoglobulin sequence is for example as set forth in SEQ ID NOs. 3 and 21. Such IgG immunoglobulin sequence can be purified efficiently on immobilized protein A. Selection of a fusion partner may also take into account structural and functional properties of immunoglobulins. Thus, for example, the heterologous peptide may be IgG3 hinge which is longer and more flexible, so it can accommodate larger CXCL11 amino acid sequences that may not fold or function properly when fused to IgGI. Another consideration may be valency; IgG are bivalent homodimers, whereas Ig subtypes like IgA and IgM may give rise to dimeric or pentameric structures, respectively, of the basic Ig homodimer unit. Other considerations in selecting the immunoglobulin portion of<!-- EPO <DP n="16"> --> the chimeric molecules of this aspect of the present invention are described in <patcit id="pcit0012" dnum="US677196A"><text>U.S. Pat. No. 6, 77,196</text></patcit>.</p><p id="p0075" num="0075">The CXCL11 fusion polypeptides of the present invention can be generated using recombinant techniques such as described by <nplcit id="ncit0028" npl-type="s"><text>Bitter et al. (1987) Methods in Enzymol. 153:516-544</text></nplcit>; <nplcit id="ncit0029" npl-type="s"><text>Studier et al. (1990) Methods in Enzymol. 185:60-89</text></nplcit>; <nplcit id="ncit0030" npl-type="s"><text>Brisson et al. (1984) Nature 310:511-514</text></nplcit>; <nplcit id="ncit0031" npl-type="s"><text>Takamatsu et al. (1987) EMBO J. 6:307-311</text></nplcit>; <nplcit id="ncit0032" npl-type="s"><text>Coruzzi et al. (1984) EMBO J. 3:1671-1680</text></nplcit>; <nplcit id="ncit0033" npl-type="s"><text>Brogli et al. (1984) Science 224:838-843</text></nplcit>; <nplcit id="ncit0034" npl-type="s"><text>Gurley et al. (1986) Mol. Cell. Biol. 6:559-565</text></nplcit> and <nplcit id="ncit0035" npl-type="b"><text>Weissbach &amp; Weissbach, 1988, Methods for Plant Molecular Biology, Academic Press, NY, Section VIII, pp 421-463</text></nplcit>.</p><p id="p0076" num="0076">The heterologous peptides may also be chemically linked to CXCL11 following the independent generation of each. Thus, the two peptides may be covalently or non-covalently linked using any linking or binding method and/or any suitable chemical linker known in the art. Such linkage can be direct or indirect, as by means of a peptide bond or via covalent bonding to an intervening linker element, such as a linker peptide or other chemical moiety, such as an organic polymer. Such chimeric peptides may be linked via bonding at the carboxy (C) or amino (N) termini of the peptides, or via bonding to internal chemical groups such as straight, branched, or cyclic side chains, internal carbon or nitrogen atoms, and the like. The exact type and chemical nature of such cross-linkers and cross linking methods is preferably adapted to the type and nature of the peptides used.</p><p id="p0077" num="0077">It will be appreciated that treatment of autoimmune diseases according to the present invention may be combined with other treatment methods known in the art (i.e., combination therapy). Thus for example, Multiple Sclerosis may be treated with the CXCL11 of the present invention in conjunction with other agents including but are not limited to, Interferon Beta 1a, Interferon Beta 1b, Glatiramer Acetate, Mitoxantrone, MethylPrednisolone, Prednisone, Prednisolone, Dexamethasone, Adreno-corticotrophic Hormone (ACTH) and Corticotrophin. The present invention therefore contemplates articles of manufacture comprising CXCL 11 and an anti-Multiple Sclerosis agent being packaged in a packaging material and identified in print, in or on the packaging material for use in the treatment of Multiple Sclerosis.</p><p id="p0078" num="0078">As mentioned, the CXCL11 polypeptides of the present invention may be used to treat inflammatory diseases other than Multiple Sclerosis. Such inflammation associated diseases and disorders are summarized infra.<!-- EPO <DP n="17"> --></p><heading id="h0004"><b><i>Inflammatory diseases associated with hypersensitivity</i></b></heading><p id="p0079" num="0079">Examples of hypersensitivity include, but are not limited to, Type I hypersensitivity, Type II hypersensitivity, Type III hypersensitivity, Type IV hypersensitivity, immediate hypersensitivity, antibody mediated hypersensitivity, immune complex mediated hypersensitivity, T lymphocyte mediated hypersensitivity and DTH.</p><p id="p0080" num="0080">Type I or immediate hypersensitivity, such as asthma.</p><p id="p0081" num="0081">Type II hypersensitivity include, but are not limited to, rheumatoid diseases, rheumatoid autoimmune diseases, rheumatoid arthritis (<nplcit id="ncit0036" npl-type="s"><text>Krenn V. et al., Histol Histopathol 2000 Jul;15 (3):791</text></nplcit>), spondylitis, ankylosing spondylitis (<nplcit id="ncit0037" npl-type="s"><text>Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189</text></nplcit>), systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus (<nplcit id="ncit0038" npl-type="s"><text>Erikson J. et al., Immunol Res 1998;17 (1-2):49</text></nplcit>), sclerosis, systemic sclerosis (<nplcit id="ncit0039" npl-type="s"><text>Renaudineau Y. et al., Clin Diagn Lab Immunol. 1999 Mar;6 (2):156</text></nplcit>); <nplcit id="ncit0040" npl-type="s"><text>Chan OT. et al., Immunol Rev 1999 Jun;169:107</text></nplcit>), glandular diseases, glandular autoimmune diseases, pancreatic autoimmune diseases, diabetes, Type I diabetes (<nplcit id="ncit0041" npl-type="s"><text>Zimmet P. Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125</text></nplcit>), thyroid diseases, autoimmune thyroid diseases, Graves' disease (<nplcit id="ncit0042" npl-type="s"><text>Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339</text></nplcit>), thyroiditis, spontaneous autoimmune thyroiditis (<nplcit id="ncit0043" npl-type="s"><text>Braley-Mullen H. and Yu S, J Immunol 2000 Dec 15;165 (12):7262</text></nplcit>), Hashimoto's thyroiditis (<nplcit id="ncit0044" npl-type="s"><text>Toyoda N. et al., Nippon Rinsho 1999 Aug;57 (8):1810</text></nplcit>), myxedema, idiopathic myxedema (<nplcit id="ncit0045" npl-type="s"><text>Mitsuma T. Nippon Rinsho. 1999 Aug;57 (8):1759</text></nplcit>); autoimmune reproductive diseases, ovarian diseases, ovarian autoimmunity (<nplcit id="ncit0046" npl-type="s"><text>Garza KM. et al., J Reprod Immunol 1998 Feb;37 (2):87</text></nplcit>), autoimmune anti-sperm infertility (<nplcit id="ncit0047" npl-type="s"><text>Diekman AB. et al., Am J Reprod Immunol. 2000 Mar;43 (3):134</text></nplcit>), repeated fetal loss (<nplcit id="ncit0048" npl-type="s"><text>Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9</text></nplcit>), neurodegenerative diseases, neurological diseases, neurological autoimmune diseases, multiple sclerosis (<nplcit id="ncit0049" npl-type="s"><text>Cross AH. et al., J Neuroimmunol 2001 Jan 1;112 (1-2):1</text></nplcit>), Alzheimer's disease (<nplcit id="ncit0050" npl-type="s"><text>Oron L. et al., J Neural Transm Suppl. 1997;49:77</text></nplcit>), myasthenia gravis (<nplcit id="ncit0051" npl-type="s"><text>Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83</text></nplcit>), motor neuropathies (<nplcit id="ncit0052" npl-type="s"><text>Kornberg AJ. J Clin Neurosci. 2000 May;7 (3):191</text></nplcit>), Guillain-Barre syndrome, neuropathies and autoimmune neuropathies (<nplcit id="ncit0053" npl-type="s"><text>Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234</text></nplcit>), myasthenic diseases, Lambert-Eaton myasthenic syndrome (<nplcit id="ncit0054" npl-type="s"><text>Takamori M. Am J Med Sci. 2000 Apr;319 (4):204</text></nplcit>), paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, cerebellar atrophies, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea,<!-- EPO <DP n="18"> --> Gilles de la Tourette syndrome, polyendocrinopathies, autoimmune polyendocrinopathies (<nplcit id="ncit0055" npl-type="s"><text>Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23</text></nplcit>); neuropathies, dysimmune neuropathies (<nplcit id="ncit0056" npl-type="s"><text>Nobile-Orazio E. et al., Electroencephalogr Clin Neurophysiol Suppl 1999;50:419</text></nplcit>); neuromyotonia, acquired neuromyotonia, arthrogryposis multiplex congenita (<nplcit id="ncit0057" npl-type="s"><text>Vincent A. et al., Ann N Y Acad Sci. 1998 May 13;841:482</text></nplcit>), cardiovascular diseases, cardiovascular autoimmune diseases, atherosclerosis (<nplcit id="ncit0058" npl-type="s"><text>Matsuura E. et al., Lupus. 1998;7 Suppl 2:S135</text></nplcit>), myocardial infarction (<nplcit id="ncit0059" npl-type="s"><text>Vaarala O. Lupus. 1998;7 Suppl 2:S132</text></nplcit>), thrombosis (<nplcit id="ncit0060" npl-type="s"><text>Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9</text></nplcit>), granulomatosis, Wegener's granulomatosis, arteritis, Takayasu's arteritis and Kawasaki syndrome (<nplcit id="ncit0061" npl-type="s"><text>Praprotnik S. et al., Wien Klin Wochenschr 2000 Aug 25;112 (15-16):660</text></nplcit>); anti-factor VIII autoimmune disease (<nplcit id="ncit0062" npl-type="s"><text>Lacroix-Desmazes S. et al., Semin Thromb Hemost.2000;26 (2):157</text></nplcit>); vasculitises, necrotizing small vessel vasculitises, microscopic polyangiitis, Churg and Strauss syndrome, glomerulonephritis, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis (<nplcit id="ncit0063" npl-type="s"><text>Noel LH. Ann Med Interne (Paris). 2000 May; 151 (3):178</text></nplcit>); antiphospholipid syndrome (<nplcit id="ncit0064" npl-type="s"><text>Flamholz R. et al., J Clin Apheresis 1999;14 (4):171</text></nplcit>); heart failure, agonist-like beta-adrenoceptor antibodies in heart failure (<nplcit id="ncit0065" npl-type="s"><text>Wallukat G. et al., Am J Cardiol. 1999 Jun 17;83 (12A):75H</text></nplcit>), thrombocytopenic purpura (<nplcit id="ncit0066" npl-type="s"><text>Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2):114</text></nplcit>); hemolytic anemia, autoimmune hemolytic anemia (<nplcit id="ncit0067" npl-type="s"><text>Efremov DG. et al., Leuk Lymphoma 1998 Jan;28 (3-4):285</text></nplcit>), gastrointestinal diseases, autoimmune diseases of the gastrointestinal tract, intestinal diseases, chronic inflammatory intestinal disease (<nplcit id="ncit0068" npl-type="s"><text>Garcia Herola A. et al., Gastroenterol Hepatol. 2000 Jan;23 (1):16</text></nplcit>), celiac disease (<nplcit id="ncit0069" npl-type="s"><text>Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122</text></nplcit>), autoimmune diseases of the musculature, myositis, autoimmune myositis, Sjogren's syndrome (<nplcit id="ncit0070" npl-type="s"><text>Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92</text></nplcit>); smooth muscle autoimmune disease (<nplcit id="ncit0071" npl-type="s"><text>Zauli D. et al., Biomed Pharmacother 1999 Jun;53 (5-6):234</text></nplcit>), hepatic diseases, hepatic autoimmune diseases, autoimmune hepatitis (<nplcit id="ncit0072" npl-type="s"><text>Manns MP. J Hepatol 2000 Aug;33 (2):326</text></nplcit>) and primary biliary cirrhosis (<nplcit id="ncit0073" npl-type="s"><text>Strassburg CP. et al., Eur J Gastroenterol Hepatol. 1999 Jun; 11 (6):595</text></nplcit>).</p><p id="p0082" num="0082">Type IV or T cell mediated hypersensitivity, include, but are not limited to, rheumatoid diseases, rheumatoid arthritis (<nplcit id="ncit0074" npl-type="s"><text>Tisch R, McDevitt HO. Proc Natl Acad Sci U S A 1994 Jan 18;91 (2):437</text></nplcit>), systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus (<nplcit id="ncit0075" npl-type="s"><text>Datta SK., Lupus 1998;7 (9):591</text></nplcit>), glandular diseases, glandular autoimmune diseases, pancreatic diseases, pancreatic autoimmune diseases, Type 1<!-- EPO <DP n="19"> --> diabetes (<nplcit id="ncit0076" npl-type="s"><text>Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647</text></nplcit>); thyroid diseases, autoimmune thyroid diseases, Graves' disease (<nplcit id="ncit0077" npl-type="s"><text>Sakata S. et al., Mol Cell Endocrinol 1993 Mar;92 (1):77</text></nplcit>); ovarian diseases (<nplcit id="ncit0078" npl-type="s"><text>Garza KM. et al., J Reprod Immunol 1998 Feb;37 (2):87</text></nplcit>), prostatitis, autoimmune prostatitis (<nplcit id="ncit0079" npl-type="s"><text>Alexander RB. et al., Urology 1997 Dec;50 (6):893</text></nplcit>), polyglandular syndrome, autoimmune polyglandular syndrome, Type I autoimmune polyglandular syndrome (<nplcit id="ncit0080" npl-type="s"><text>Hara T. et al., Blood. 1991 Mar 1;77 (5):1127</text></nplcit>), neurological diseases, autoimmune neurological diseases, multiple sclerosis, neuritis, optic neuritis (<nplcit id="ncit0081" npl-type="s"><text>Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544</text></nplcit>), myasthenia gravis (<nplcit id="ncit0082" npl-type="s"><text>Oshima M. et al., Eur J Immunol 1990 Dec;20 (12):2563</text></nplcit>), stiff-man syndrome (<nplcit id="ncit0083" npl-type="s"><text>Hiemstra HS. et al., Proc Natl Acad Sci U S A 2001 Mar 27;98 (7):3988</text></nplcit>), cardiovascular diseases, cardiac autoimmunity in Chagas' disease (<nplcit id="ncit0084" npl-type="s"><text>Cunha-Neto E. et al., J Clin Invest 1996 Oct 15;98 (8):1709</text></nplcit>), autoimmune thrombocytopenic purpura (<nplcit id="ncit0085" npl-type="s"><text>Semple JW. et al., Blood 1996 May 15;87 (10):4245</text></nplcit>), anti-helper T lymphocyte autoimmunity (<nplcit id="ncit0086" npl-type="s"><text>Caporossi AP. et al., Viral Immunol 1998;11 (1):9</text></nplcit>), hemolytic anemia (<nplcit id="ncit0087" npl-type="s"><text>Sallah S. et al., Ann Hematol 1997 Mar;74 (3):139</text></nplcit>), hepatic diseases, hepatic autoimmune diseases, hepatitis, chronic active hepatitis (<nplcit id="ncit0088" npl-type="s"><text>Franco A. et al., Clin Immunol Immunopathol 1990 Mar;54 (3):382</text></nplcit>), biliary cirrhosis, primary biliary cirrhosis (<nplcit id="ncit0089" npl-type="s"><text>Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551</text></nplcit>), nephric diseases, nephric autoimmune diseases, nephritis, interstitial nephritis (<nplcit id="ncit0090" npl-type="s"><text>Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140</text></nplcit>), connective tissue diseases, ear diseases, autoimmune connective tissue diseases, autoimmune ear disease (<nplcit id="ncit0091" npl-type="s"><text>Yoo TJ. et al., Cell Immunol 1994 Aug;157 (1):249</text></nplcit>), disease of the inner ear (<nplcit id="ncit0092" npl-type="s"><text>Gloddek B. et al., Ann N Y Acad Sci 1997 Dec 29;830:266</text></nplcit>), skin diseases, cutaneous diseases, dermal diseases, bullous skin diseases, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.</p><p id="p0083" num="0083">Examples of delayed type hypersensitivity include, but are not limited to, contact dermatitis and drug eruption.</p><p id="p0084" num="0084">Examples of types of T lymphocyte mediating hypersensitivity include, but are not limited to, helper T lymphocytes and cytotoxic T lymphocytes.</p><p id="p0085" num="0085">Examples of helper T lymphocyte-mediated hypersensitivity include, but are not limited to, T<sub>h</sub>1 lymphocyte mediated hypersensitivity and T<sub>h</sub>2 lymphocyte mediated hypersensitivity.</p><heading id="h0005"><b><i>Autoimmune diseases</i></b></heading><p id="p0086" num="0086">Include, but are not limited to, cardiovascular diseases, rheumatoid diseases, glandular diseases, gastrointestinal diseases, cutaneous diseases, hepatic diseases,<!-- EPO <DP n="20"> --> neurological diseases, muscular diseases, nephric diseases, diseases related to reproduction, connective tissue diseases and systemic diseases.</p><p id="p0087" num="0087">Examples of autoimmune cardiovascular diseases include, but are not limited to atherosclerosis (<nplcit id="ncit0093" npl-type="s"><text>Matsuura E. et al., Lupus. 1998;7 Suppl 2:S 135</text></nplcit>), myocardial infarction (<nplcit id="ncit0094" npl-type="s"><text>Vaarala O. Lupus. 1998;7 Suppl 2:S132</text></nplcit>), thrombosis (<nplcit id="ncit0095" npl-type="s"><text>Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9</text></nplcit>), Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome (Praprotnik S. <i>et al.,</i> <nplcit id="ncit0096" npl-type="s"><text>Wien Klin Wochenschr 2000 Aug 25;112 (15-16):660</text></nplcit>), anti-factor VIII autoimmune disease (Lacroix-Desmazes S. <i>et al.,</i> Semin Thromb Hemost.2000;26 (2):157), necrotizing small vessel vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal necrotizing and crescentic glomerulonephritis (<nplcit id="ncit0097" npl-type="s"><text>Noel LH. Ann Med Interne (Paris). 2000 May;151 (3):178</text></nplcit>), antiphospholipid syndrome (<nplcit id="ncit0098" npl-type="s"><text>Flamholz R. et al., J Clin Apheresis 1999;14 (4):171</text></nplcit>), antibody-induced heart failure (<nplcit id="ncit0099" npl-type="s"><text>Wallukat G. et al., Am J Cardiol. 1999 Jun 17;83 (12A):75H</text></nplcit>), thrombocytopenic purpura (<nplcit id="ncit0100" npl-type="s"><text>Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2):114</text></nplcit>; <nplcit id="ncit0101" npl-type="s"><text>Semple JW. et al., Blood 1996 May 15;87 (10):4245</text></nplcit>), autoimmune hemolytic anemia (<nplcit id="ncit0102" npl-type="s"><text>Efremov DG. et al., Leuk Lymphoma 1998 Jan;28 (3-4):285</text></nplcit>; <nplcit id="ncit0103" npl-type="s"><text>Sallah S. et al., Ann Hematol 1997 Mar;74 (3):139</text></nplcit>), cardiac autoimmunity in Chagas' disease (<nplcit id="ncit0104" npl-type="s"><text>Cunha-Neto E. et al., J Clin Invest 1996 Oct 15;98 (8):1709</text></nplcit>) and anti-helper T lymphocyte autoimmunity (<nplcit id="ncit0105" npl-type="s"><text>Caporossi AP. et al., Viral Immunol 1998;11 (1):9</text></nplcit>).</p><p id="p0088" num="0088">Examples of autoimmune rheumatoid diseases include, but are not limited to rheumatoid arthritis (<nplcit id="ncit0106" npl-type="s"><text>Krenn V. et al., Histol Histopathol 2000 Jun;15 (3):791</text></nplcit>; <nplcit id="ncit0107" npl-type="s"><text>Tisch R, McDevitt HO. Proc Natl Acad Sci units S A 1994 Jan 18;91 (2):437</text></nplcit>) and ankylosing spondylitis (<nplcit id="ncit0108" npl-type="s"><text>Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189</text></nplcit>).</p><p id="p0089" num="0089">Examples of autoimmune glandular diseases include, but are not limited to, pancreatic disease, Type I diabetes, thyroid disease, Graves' disease, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome. diseases include, but are not limited to autoimmune diseases of the pancreas, Type 1 diabetes (<nplcit id="ncit0109" npl-type="s"><text>Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647</text></nplcit>; <nplcit id="ncit0110" npl-type="s"><text>Zimmet P. Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125</text></nplcit>), autoimmune thyroid diseases, Graves' disease (<nplcit id="ncit0111" npl-type="s"><text>Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339</text></nplcit>; <nplcit id="ncit0112" npl-type="s"><text>Sakata S. et al., Mol Cell Endocrinol 1993 Mar;92 (1):77</text></nplcit>), spontaneous autoimmune thyroiditis (<nplcit id="ncit0113" npl-type="s"><text>Braley-Mullen H. and Yu S, J Immunol 2000 Dec 15;165 (12):7262</text></nplcit>), Hashimoto's thyroiditis (<nplcit id="ncit0114" npl-type="s"><text>Toyoda N. et al., Nippon Rinsho 1999 Aug;57<!-- EPO <DP n="21"> --> (8):1810</text></nplcit>), idiopathic myxedema (<nplcit id="ncit0115" npl-type="s"><text>Mitsuma T. Nippon Rinsho. 1999 Aug;57 (8):1759</text></nplcit>), ovarian autoimmunity (<nplcit id="ncit0116" npl-type="s"><text>Garza KM. el al., J Reprod Immunol 1998 Feb;37 (2):87</text></nplcit>), autoimmune anti-sperm infertility (<nplcit id="ncit0117" npl-type="s"><text>Diekman AB. et al., Am J Reprod Immunol. 2000 Mar;43 (3):134</text></nplcit>), autoimmune prostatitis (<nplcit id="ncit0118" npl-type="s"><text>Alexander RB. et al., Urology 1997 Dec;50 (6):893</text></nplcit>) and Type I autoimmune polyglandular syndrome (<nplcit id="ncit0119" npl-type="s"><text>Hara T. et al., Blood. 1991 Mar 1;77 (5):1127</text></nplcit>).</p><p id="p0090" num="0090">Examples of autoimmune gastrointestinal diseases include, but are not limited to, chronic inflammatory intestinal diseases (<nplcit id="ncit0120" npl-type="s"><text>Garcia Herola A. et al., Gastroenterol Hepatol. 2000 Jan;23 (1):16</text></nplcit>), celiac disease (<nplcit id="ncit0121" npl-type="s"><text>Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122</text></nplcit>), colitis, ileitis and Crohn's disease.</p><p id="p0091" num="0091">Examples of autoimmune cutaneous diseases include, but are not limited to, autoimmune bullous skin diseases, such as, but are not limited to, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.</p><p id="p0092" num="0092">Examples of autoimmune hepatic diseases include, but are not limited to, hepatitis, autoimmune chronic active hepatitis (<nplcit id="ncit0122" npl-type="s"><text>Franco A. et al., Clin Immunol Immunopathol 1990 Mar;54 (3):382</text></nplcit>), primary biliary cirrhosis (<nplcit id="ncit0123" npl-type="s"><text>Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551</text></nplcit>; <nplcit id="ncit0124" npl-type="s"><text>Strassburg CP. et al., Eur J Gastroenterol Hepatol. 1999 Jun; 11 (6):595</text></nplcit>) and autoimmune hepatitis (<nplcit id="ncit0125" npl-type="s"><text>Manns MP. J Hepatol 2000 Aug;33 (2):326</text></nplcit>).</p><p id="p0093" num="0093">Examples of autoimmune neurological diseases include, but are not limited to, multiple sclerosis (<nplcit id="ncit0126" npl-type="s"><text>Cross AH. et al., J Neuroimmunol 2001 Jan 1;112 (1-2):1</text></nplcit>), Alzheimer's disease (<nplcit id="ncit0127" npl-type="s"><text>Oron L. et al., J Neural Transm Suppl. 1997;49:77</text></nplcit>), myasthenia gravis (<nplcit id="ncit0128" npl-type="s"><text>Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83</text></nplcit>; <nplcit id="ncit0129" npl-type="s"><text>Oshima M. et al., Eur J Immunol 1990 Dec;20 (12):2563</text></nplcit>), neuropathies, motor neuropathies (<nplcit id="ncit0130" npl-type="s"><text>Komberg AJ. J Clin Neurosci. 2000 May;7 (3):191</text></nplcit>); Guillain-Barre syndrome and autoimmune neuropathies (<nplcit id="ncit0131" npl-type="s"><text>Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234</text></nplcit>), myasthenia, Lambert-Eaton myasthenic syndrome (<nplcit id="ncit0132" npl-type="s"><text>Takamori M. Am J Med Sci. 2000 Apr;319 (4):204</text></nplcit>); paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy and stiff-man syndrome (<nplcit id="ncit0133" npl-type="s"><text>Hiemstra HS. et al., Proc Natl Acad Sci units S A 2001 Mar 27;98 (7):3988</text></nplcit>); non-paraneoplastic stiff man syndrome, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome and autoimmune polyendocrinopathies (<nplcit id="ncit0134" npl-type="s"><text>Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23</text></nplcit>); dysimmune neuropathies (<nplcit id="ncit0135" npl-type="s"><text>Nobile-Orazio E. et al., Electroencephalogr Clin Neurophysiol Suppl 1999;50:419</text></nplcit>); acquired<!-- EPO <DP n="22"> --> neuromyotonia, arthrogryposis multiplex congenita (<nplcit id="ncit0136" npl-type="s"><text>Vincent A. et al., Ann N Y Acad Sci. 1998 May 13;841:482</text></nplcit>), neuritis, optic neuritis (<nplcit id="ncit0137" npl-type="s"><text>Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544</text></nplcit>) and neurodegenerative diseases.</p><p id="p0094" num="0094">Examples of autoimmune muscular diseases include, but are not limited to, myositis, autoimmune myositis and primary Sjogren's syndrome (<nplcit id="ncit0138" npl-type="s"><text>Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92</text></nplcit>) and smooth muscle autoimmune disease (<nplcit id="ncit0139" npl-type="s"><text>Zauli D. et al., Biomed Pharmacother 1999 Jun;53 (5-6):234</text></nplcit>).</p><p id="p0095" num="0095">Examples of autoimmune nephric diseases include, but are not limited to, nephritis and autoimmune interstitial nephritis (<nplcit id="ncit0140" npl-type="s"><text>Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140</text></nplcit>).</p><p id="p0096" num="0096">Examples of autoimmune diseases related to reproduction include, but are not limited to, repeated fetal loss (<nplcit id="ncit0141" npl-type="s"><text>Tincani A. et al., Lupus 1998;7 Suppl 2:S 107-9</text></nplcit>).</p><p id="p0097" num="0097">Examples of autoimmune connective tissue diseases include, but are not limited to, ear diseases, autoimmune ear diseases (<nplcit id="ncit0142" npl-type="s"><text>Yoo TJ. et al., Cell Immunol 1994 Aug;157 (1):249</text></nplcit>) and autoimmune diseases of the inner ear (<nplcit id="ncit0143" npl-type="s"><text>Gloddek B. et al., Ann N Y Acad Sci 1997 Dec 29;830:266</text></nplcit>).</p><p id="p0098" num="0098">Examples of autoimmune systemic diseases include, but are not limited to, systemic lupus erythematosus (<nplcit id="ncit0144" npl-type="s"><text>Erikson J. et al., Immunol Res 1998;17 (1-2):49</text></nplcit>) and systemic sclerosis (<nplcit id="ncit0145" npl-type="s"><text>Renaudineau Y. et al., Clin Diagn Lab Immunol. 1999 Mar;6 (2):156</text></nplcit>); <nplcit id="ncit0146" npl-type="s"><text>Chan OT. et al., Immunol Rev 1999 Jun;169:107</text></nplcit>).</p><heading id="h0006"><b><i>Infectious diseases</i></b></heading><p id="p0099" num="0099">Examples of infectious diseases include, but are not limited to, chronic infectious diseases, subacute infectious diseases, acute infectious diseases, viral diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, mycoplasma diseases and prion diseases.</p><heading id="h0007"><b><i>Graft rejection diseases</i></b></heading><p id="p0100" num="0100">Examples of diseases associated with transplantation of a graft include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection and graft versus host disease.</p><heading id="h0008"><b><i>Allergic diseases</i></b></heading><p id="p0101" num="0101">Examples of allergic diseases include, but are not limited to, asthma, hives, urticaria, pollen allergy, dust mite allergy, venom allergy, cosmetics allergy, latex allergy, chemical allergy, drug allergy, insect bite allergy, animal dander allergy, stinging plant allergy, poison ivy allergy and food allergy.<!-- EPO <DP n="23"> --></p><heading id="h0009"><b><i>Cancerous diseases</i></b></heading><p id="p0102" num="0102">Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Particular examples of cancerous diseases but are not limited to: Myeloid leukemia such as Chronic myelogenous leukemia. Acute myelogenous leukemia with maturation. Acute promyelocytic leukemia, Acute nonlymphocytic leukemia with increased basophils, Acute monocytic leukemia. Acute myelomonocytic leukemia with eosinophilia; Malignant lymphoma, such as Birkitt's Non-Hodgkin's; Lymphoctyic leukemia, such as Acute lumphoblastic leukemia. Chronic lymphocytic leukemia; Myeloproliferative diseases, such as Solid tumors Benign Meningioma, Mixed tumors of salivary gland, Colonic adenomas; Adenocarcinomas, such as Small cell lung cancer, Kidney, Uterus, Prostate, Bladder, Ovary, Colon, Sarcomas, Liposarcoma, myxoid, Synovial sarcoma, Rhabdomyosarcoma (alveolar), Extraskeletel myxoid chonodrosarcoma, Ewing's tumor; other include Testicular and ovarian dysgerminoma, Retinoblastoma, Wilms' tumor, Neuroblastoma, Malignant melanoma, Mesothelioma, breast, skin, prostate, and ovarian.</p><p id="p0103" num="0103">CXCL11 of the present invention can be administered to the subject <i>per se,</i> or as part of a pharmaceutical composition, which also includes a physiologically acceptable carrier. The purpose of a pharmaceutical composition is to facilitate administration of the active ingredient to an organism.</p><p id="p0104" num="0104">As used herein, a "pharmaceutical composition" refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.</p><p id="p0105" num="0105">As used herein, the term "active ingredient" refers to the preparation accountable for the intended biological effect.</p><p id="p0106" num="0106">Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutically acceptable carrier" which may be interchangeably used refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases. One of the ingredients included in the pharmaceutically acceptable carrier can be for example polyethylene glycol (PEG), a biocompatible polymer with a wide range of solubility in both organic and aqueous media [Mutter et al. (1979)].<!-- EPO <DP n="24"> --></p><p id="p0107" num="0107">Herein the term "excipient" refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.</p><p id="p0108" num="0108">Techniques for formulation and administration of drugs may be found in "<nplcit id="ncit0147" npl-type="b"><text>Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest editi</text></nplcit>on, which is incorporated herein by reference.</p><p id="p0109" num="0109">Suitable routes of administration may, for example, include oral, rectal, transmucosal, especially transnasal, intestinal or parenteral delivery, including intramuscular, subcutaneous and intramedullary injections as well as intrathecal, direct intraventricular, intravenous, inrtaperitoneal, intranasal, or intraocular injections.</p><p id="p0110" num="0110">Alternately, one may administer a preparation in a local rather than systemic manner, for example, via injection of the preparation directly into a specific region of a patient's body.</p><p id="p0111" num="0111">Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.</p><p id="p0112" num="0112">Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.</p><p id="p0113" num="0113">For injection, the active ingredients of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.</p><p id="p0114" num="0114">For oral administration, the pharmaceutical composition can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the pharmaceutical composition to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for oral ingestion by a patient. Pharmacological preparations for oral use can be made using a solid<!-- EPO <DP n="25"> --> excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries as desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, and sodium carbomethylcellulose; and/or physiologically acceptable polymers such as polyvinylpyrrolidone (PVP). If desired, disintegrating agents, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof, such as sodium alginate, may be added.</p><p id="p0115" num="0115">Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.</p><p id="p0116" num="0116">Pharmaceutical compositions, which can be used orally, include push-fit capsules made of gelatin as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules may contain the active ingredients in admixture with filler such as lactose, binders such as starches, lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active ingredients may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for the chosen route of administration.</p><p id="p0117" num="0117">For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.</p><p id="p0118" num="0118">For administration by nasal inhalation, the active ingredients for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in a dispenser may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.<!-- EPO <DP n="26"> --></p><p id="p0119" num="0119">The preparations described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. The compositions may be suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.</p><p id="p0120" num="0120">Pharmaceutical compositions for parenteral administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides or liposomes. Aqueous injection suspensions may contain substances, which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the active ingredients to allow for the preparation of highly concentrated solutions.</p><p id="p0121" num="0121">Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., a sterile, pyrogen-free, water-based solution, before use.</p><p id="p0122" num="0122">The pharmaceutical composition of the present invention may also be formulated in rectal compositions such as suppositories or retention enemas, using, for example, conventional suppository bases such as cocoa butter or other glycerides.</p><p id="p0123" num="0123">Pharmaceutical compositions suitable for use in the context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. More specifically, a "therapeutically effective amount" means an amount of active ingredients (e.g., a nucleic acid construct) effective to prevent, alleviate, or ameliorate symptoms of a disorder (e.g., ischemia) or prolong the survival of the subject being treated.</p><p id="p0124" num="0124">Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.</p><p id="p0125" num="0125">For any preparation used in the methods of the invention, the dosage or the therapeutically effective amount can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.<!-- EPO <DP n="27"> --></p><p id="p0126" num="0126">Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g., <nplcit id="ncit0148" npl-type="b"><text>Fingl, E. et al. (1975), "The Pharmacological Basis of Therapeutics," Ch. 1, p.1</text></nplcit>.)</p><p id="p0127" num="0127">Dosage amount and administration intervals may be adjusted individually to provide sufficient plasma or brain levels of the active ingredient to induce or suppress the biological effect (i.e., minimally effective concentration, MEC). The MEC will vary for each preparation, but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.</p><p id="p0128" num="0128">Depending on the severity and responsiveness of the condition to be treated, dosing can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks, or until cure is effected or diminution of the disease state is achieved.</p><p id="p0129" num="0129">The amount of a composition to be administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.</p><p id="p0130" num="0130">Compositions of the present invention may, if desired, be presented in a pack or dispenser device, such as an FDA-approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser device may also be accompanied by a notice in a form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions for human or veterinary administration. Such notice, for example, may include labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a pharmaceutically acceptable<!-- EPO <DP n="28"> --> carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition, as further detailed above.</p><p id="p0131" num="0131">The discovery that CXCL 11 polarizes T cells into T regulatory cells which secrete anti-inflammatory cytokines (e.g. IL-10 and IL-4) instead of pro-inflammatory cytokines (e.g., IL-12 and TNF-α), see <figref idrefs="f0008 f0009">Figures 10A-K</figref>, suggests the use of CXCL11 in isolated settings so as to avoid undesired side effects. As depicted in detail in Examples 4 and 6 hereinbelow, treatment of multiple sclerosis (in a murine model) by ex vivo therapy via administration of antigen specific, IL-10 producing T cells selected in the presence of CXCL11-IgG lead to fast remission in active disease.</p><p id="p0132" num="0132">Thus, according to another aspect of the present invention there is provided a method of treating an autoimmune disease in a subject in need thereof, the method comprising ex vivo contacting T cells with CXCL11 under conditions which result in generation of regulatory T cells and administering the regulatory T cells to the subject, thereby treating the autoimmune disease in the subject.</p><p id="p0133" num="0133">As used herein the term "ex vivo contacting" refers to the process of isolating T cells from a body and culturing them with CXCL11, as for example in a culture dish or by an automated machine (e.g. cell dialysis apparatus which by automated settings separates cells from body fluids and cultures them with the appropriate substances in a sterile environment), as to enable direct contact of the cells with CXCL11.</p><p id="p0134" num="0134">Thus, T cells can be isolated from an autologous origin (i.e. from the multiple sclerosis affected subject), from a syngeneic donor, from an allogeneic donor or from a xenogeneic donor. The T cells may also be obtained from a multiple sclerosis affected subject undergoing CXCL11 treatment.</p><p id="p0135" num="0135">Furthermore, the T cells may be comprised in a crude blood sample, in PBMC, or further purified. In an exemplary embodiment, the isolated T cells are purified CD4+ T cells such as naive CD4+ T cells. To avoid the effects of graft versus host disease (GVHD) exhibited by CD8+ T cells (i.e. cytotoxic T cells), purification of CD4+ T cells, rather than CD8+ T cells is effected.</p><p id="p0136" num="0136">Several techniques are known in the art for isolating T cells [see for example, <nplcit id="ncit0149" npl-type="s"><text>Leavitt et al., Hum. Gene Ther. 5: 1115-1120 (1994</text></nplcit>)]. The expression of surface markers facilitates identification and purification of T cells. Methods of identification and isolation of T cells include FACS, panning with magnetic beads and human T-cell subset columns.<!-- EPO <DP n="29"> --> Cells isolated according to the teachings of the present invention should stay sterile and preferably maintained out of the body for a minimal time period.</p><p id="p0137" num="0137">Subsequent to cell isolation, the T cells are subjected to culture in the presence of CXCL11. Such culture conditions are described in detail in Example 7 (in the Example section hereinbelow). For example, the isolated T cells (about 300,000 cell/ml) may be cultured in the presence of rhCXCL11 (10 ng/ml) and a stimulatory peptide (e.g. anti-CD3ε mAb and/or anti-CD28 mAb at a concentration of 2 µg/ml), in a humidified 7.5 % CO<sub>2</sub> atmosphere at 37 °C for 48 hours.</p><p id="p0138" num="0138">Such culturing conditions enable polarization of the isolated T cells into regulatory T cells. In an exemplary embodiment, such culturing conditions polarize T cells to become IL-10 and/or IL-4 secreting cells. Furthermore, following these culturing conditions, a reduction in secretion of pro-inflammatory cytokines (e.g. IFN-γ) is noted.</p><p id="p0139" num="0139">As used herein the terms "regulatory T cells" refers to the subset of T cells, also known as suppressor T cells, which are a specialized subpopulation of T cells that act to suppress activation of the immune system and thereby maintain immune system homeostasis and tolerance to self-antigens. CD4+ regulatory T cells may express the membrane markers CD25 and/or Foxp3.</p><p id="p0140" num="0140">CXCL11 treated regulatory T cells are then administered to the subject (e.g., a subject diagnosed with Multiple Sclerosis as described hereinabove).</p><p id="p0141" num="0141">Those skilled in the art are capable of determining when and how to administer the T cells to thereby treat Multiple Sclerosis. The administration can be carried out via local injection, by administration into the systemic (e. g., via the blood stream or the peritoneal cavity) or portal circulation system, or by any other practical means (see for example, <patcit id="pcit0013" dnum="WO2001078752A"><text>WO/2001/078752</text></patcit>).</p><p id="p0142" num="0142">According to an embodiment of the present teachings, the regulatory T cells are specifically selected (i.e. isolated from the cell culture) prior to administering to the subject. Methods of isolating regulatory T cells are described hereinabove.</p><p id="p0143" num="0143">As depicted above, the T cells used for ex vivo therapy according to the present teachings may be from a non-syngeneic source (i.e. from an allogeneic or xenogeneic donor). Although administration of purified regulatory T cells should not cause GVHD, in cases where there is a risk of GVHD or occurrence of GVHD, any GVHD treatment protocol may be employed. Such treatments may include administration of immunosuppressant drugs (e.g., sirolimus, tacrolimus, cyclosporine, CTLA4-Ig, anti-CD40L<!-- EPO <DP n="30"> --> antibody or rapamycin) which may be administered individually or in combination. Immunosuppressant drugs may be administered prior to, concomitantly with, or following administration of the regulatory T cells.</p><p id="p0144" num="0144">Furthermore, administering non-syngeneic cells may cause rejection of the cells used for ex vivo therapy. Several approaches have been developed to reduce the likelihood of rejection of these non-syngeneic cells. These include either suppressing the recipient immune system (as described above) or encapsulating the non-autologous T cells in immunoisolating, semipermeable membranes prior to administration.</p><p id="p0145" num="0145">Encapsulation techniques are generally classified as microencapsulation, involving small spherical vehicles, and macroencapsulation, involving larger flat-sheet and hollow-fiber membranes (<nplcit id="ncit0150" npl-type="s"><text>Uludag, H. et al. (2000). Technology of mammalian cell encapsulation. Adv Drug Deliv Rev 42, 29-64</text></nplcit>).</p><p id="p0146" num="0146">Methods of preparing microcapsules are known in the art and include for example those disclosed in: <nplcit id="ncit0151" npl-type="s"><text>Lu, M. Z. et al. (2000). Cell encapsulation with alginate and alpha-phenoxycinnamylidene-acetylated poly(allylamine). Biotechnol Bioeng 70, 479-483</text></nplcit>; <nplcit id="ncit0152" npl-type="s"><text>Chang, T. M. and Prakash, S. (2001) Procedures for microencapsulation of enzymes, cells and genetically engineered microorganisms. Mol Biotechnol 17, 249-260</text></nplcit>; and <nplcit id="ncit0153" npl-type="s"><text>Lu, M. Z., et al. (2000). A novel cell encapsulation method using photosensitive poly(allylamine alpha-cyanocinnamylideneacetate). J Microencapsul 17, 245-521</text></nplcit>.</p><p id="p0147" num="0147">For example, microcapsules are prepared using modified collagen in a complex with a ter-polymer shell of 2-hydroxyethyl methylacrylate (HEMA), methacrylic acid (MAA), and methyl methacrylate (MMA), resulting in a capsule thickness of 2-5 µm. Such microcapsules can be further encapsulated with an additional 2-5 µm of ter-polymer shells in order to impart a negatively charged smooth surface and to minimize plasma protein absorption (<nplcit id="ncit0154" npl-type="s"><text>Chia, S. M. et al. (2002). Multi-layered microcapsules for cell encapsulation. Biomaterials 23, 849-856</text></nplcit>).</p><p id="p0148" num="0148">Other microcapsules are based on alginate, a marine polysaccharide (<nplcit id="ncit0155" npl-type="s"><text>Sambanis, A. (2003). Encapsulated islets in diabetes treatment. Diabetes Thechnol Ther 5, 665-668</text></nplcit>), or its derivatives. For example, microcapsules can be prepared by the polyelectrolyte complexation between the polyanions sodium alginate and sodium cellulose sulphate and the polycation poly(methylene-co-guanidine) hydrochloride in the presence of calcium chloride.<!-- EPO <DP n="31"> --></p><p id="p0149" num="0149">It will be appreciated that cell encapsulation is improved when smaller capsules are used, Thus, for instance, the quality control, mechanical stability, diffusion properties, and in vitro activities of encapsulated cells improved when the capsule size was reduced from 1 mm to 400 µm (<nplcit id="ncit0156" npl-type="s"><text>Canaple, L. et al. (2002). Improving cell encapsulation through size control. J Biomater Sci Polym Ed 13, 783-96</text></nplcit>). Moreover, nanoporous biocapsules with well-controlled pore size as small as 7 nm, tailored surface chemistries, and precise microarchitectures were found to successfully immunoisolate microenvironments for cells (See: <nplcit id="ncit0157" npl-type="s"><text>Williams, D. (1999). Small is beautiful: microparticle and nanoparticle technology in medical devices. Med Device Technol 10, 6-9</text></nplcit>; and <nplcit id="ncit0158" npl-type="s"><text>Desai, T. A. (2002). Microfabrication technology for pancreatic cell encapsulation. Expert Opin Biol Ther 2, 633-646</text></nplcit>).</p><p id="p0150" num="0150">Treatment of an autoimmune disease, such as multiple sclerosis, according to the present teachings may be repeated as required, such as during relapse.</p><p id="p0151" num="0151">Thus, the present invention provides compositions and methods of treating MS using in vivo and ex-vivo settings.</p><p id="p0152" num="0152">As used herein the term "about" refers to ± 10 %.</p><p id="p0153" num="0153">Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples. Additionally, each of the various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.</p><heading id="h0010"><b>EXAMPLES</b></heading><p id="p0154" num="0154">Reference is now made to the following examples, which together with the above descriptions, illustrate the invention.</p><p id="p0155" num="0155">Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical; microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "<nplcit id="ncit0159" npl-type="b"><text>Molecular Cloning: A laboratory Manual" Sambrook et al., (1989</text></nplcit>); "<nplcit id="ncit0160" npl-type="b"><text>Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed. (1994</text></nplcit>); <nplcit id="ncit0161" npl-type="b"><text>Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989</text></nplcit>); <nplcit id="ncit0162" npl-type="b"><text>Perbal, "A Practical Guide to Molecular Cloning", John Wiley &amp; Sons, New York<!-- EPO <DP n="32"> --> (1988</text></nplcit>); <nplcit id="ncit0163" npl-type="b"><text>Watson et al., "Recombinant DNA", Scientific American Books, New York</text></nplcit>; <nplcit id="ncit0164" npl-type="b"><text>Birren et al. (eds) "Genome Analysis: A Laboratory Manual Serves", Vols. 1-4, Cold Spring Harbour Laboratory Press, New York (1998</text></nplcit>); methodologies as set forth in <patcit id="pcit0014" dnum="US4666828A"><text>U.S. Pat. Nos. 4,666,828</text></patcit>; <patcit id="pcit0015" dnum="US4683202A"><text>4,683,202</text></patcit>; <patcit id="pcit0016" dnum="US4801531A"><text>4,801,531</text></patcit>; <patcit id="pcit0017" dnum="US5192659A"><text>5,192,659</text></patcit> and <patcit id="pcit0018" dnum="US5272057A"><text>5,272,057</text></patcit>; "<nplcit id="ncit0165" npl-type="b"><text>Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J. E., ed. (1994</text></nplcit>); "<nplcit id="ncit0166" npl-type="b"><text>Culture of Animal Cells - A Manual of Basic Technique" by Freshney, Wiley-Liss, N. Y. (1994), Third Editi</text></nplcit>on; "<nplcit id="ncit0167" npl-type="b"><text>Current Protocols in Immunology" Volumes I-III Coligan J. E., ed. (1994</text></nplcit>); <nplcit id="ncit0168" npl-type="b"><text>Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton &amp; Lange, Norwalk, CT (1994</text></nplcit>); <nplcit id="ncit0169" npl-type="b"><text>Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980</text></nplcit>); available immunoassays are extensively described in the patent and scientific literature, see, for example, <patcit id="pcit0019" dnum="US3791932A"><text>U.S. Pat. Nos. 3,791,932</text></patcit>; <patcit id="pcit0020" dnum="US3839153A"><text>3,839,153</text></patcit>; <patcit id="pcit0021" dnum="US3850752A"><text>3,850,752</text></patcit>; <patcit id="pcit0022" dnum="US3850578A"><text>3,850,578</text></patcit>; <patcit id="pcit0023" dnum="US3853987A"><text>3,853,987</text></patcit>; <patcit id="pcit0024" dnum="US3867517A"><text>3,867,517</text></patcit>; <patcit id="pcit0025" dnum="US3879262A"><text>3,879,262</text></patcit>; <patcit id="pcit0026" dnum="US3901654A"><text>3,901,654</text></patcit>; <patcit id="pcit0027" dnum="US3935074A"><text>3,935,074</text></patcit>; <patcit id="pcit0028" dnum="US3984533A"><text>3,984,533</text></patcit>; <patcit id="pcit0029" dnum="US3996345A"><text>3,996,345</text></patcit>; <patcit id="pcit0030" dnum="US4034074A"><text>4,034,074</text></patcit>; <patcit id="pcit0031" dnum="US4098876A"><text>4,098,876</text></patcit>; <patcit id="pcit0032" dnum="US4879219A"><text>4,879,219</text></patcit>: <patcit id="pcit0033" dnum="US5011771A"><text>5,011,771</text></patcit> and<patcit id="pcit0034" dnum="US5281521A"><text> 5,281.521</text></patcit>; "<nplcit id="ncit0170" npl-type="b"><text>Oligonucleotide Synthesis" Gait, M. J., ed. (1984</text></nplcit>); "<nplcit id="ncit0171" npl-type="b"><text>Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985</text></nplcit>); "<nplcit id="ncit0172" npl-type="b"><text>Transcription and Translation" flames, B. D., and Higgins S. J., eds. (1984</text></nplcit>); "<nplcit id="ncit0173" npl-type="b"><text>Animal Cell Culture" Freshney, R. I., ed. (1986</text></nplcit>); "<nplcit id="ncit0174" npl-type="b"><text>Immobilized Cells and Enzymes" IRL Press, (1986</text></nplcit>); "<nplcit id="ncit0175" npl-type="s"><text>A Practical Guide to Molecular Cloning" Perbal, B., (1984</text></nplcit>) and "<nplcit id="ncit0176" npl-type="b"><text>Methods in Enzymology" Vol. I-317, Academic Press</text></nplcit>; "<nplcit id="ncit0177" npl-type="b"><text>PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990</text></nplcit>); <nplcit id="ncit0178" npl-type="b"><text>Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL Press (1996</text></nplcit>); all of which are incorpotaed by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader.</p><heading id="h0011"><b>EXAMPLE 1</b></heading><heading id="h0012"><b><i>Neutralizing CXCL10 and CXCL9 suppresses Experimental Autoimmune Encephalomyelitis (EAE) while neutralizing CXCL11 aggravates its manifestation</i></b></heading><p id="p0156" num="0156">In order to elucidate the role of the different CXCR3 ligands (CXCL9, CXCL10 and CXCL11) in the regulation of Multiple Sclerosis, antibodies generated against each of the three CXCR3 ligands were produced and administered to mice during experimental autoimmune encephalomyelitis (EAE) - an experimentally induced autoimmune disease of the CNS, which serves as an experimental animal model for multiple sclerosis.<!-- EPO <DP n="33"> --></p><heading id="h0013"><b>MATERIALS AND METHODS</b></heading><heading id="h0014"><b><i>Animals</i></b></heading><p id="p0157" num="0157">6-week-old female C57BL/6 mice were purchased from Harlan (Jerusalem, Israel) and maintained under specific pathogen-free conditions.</p><heading id="h0015"><b><i>Peptide Antigens</i></b></heading><p id="p0158" num="0158">Myelin oligodendrocyte glycoprotein MOG<sub>35-55</sub> (SEQ ID NO: 31) was constructed by the PAN facility of the Beckman Center of Stanford University. After purification by HPLC, the sequence was confirmed by amino acid analysis and the mass was checked by mass spectroscopy. Purification of the peptide used in this invention was &gt; 95 %.</p><heading id="h0016"><b><i>Induction of active EAE</i></b></heading><p id="p0159" num="0159">Active induction of EAE was induced by immunizing C57BL\6 female mice with MOG<sub>P35</sub>-<sub>55</sub>/CFA as previously described by Tompkins et al. [<nplcit id="ncit0179" npl-type="s"><text>Tompkins et al., J Immunol (2002) 168:4173-83</text></nplcit>]. Mice were monitored daily for clinical signs by an observer blind to the treatment protocol. EAE was scored as follows: 0 - clinically normal; 1 - flaccid tail; 2 - hind limb paralysis; 3 - total hind limb paralysis, accompanied by an apparent front limb paralysis; 4 - total hind limb and front limb paralysis; and 5- death.</p><heading id="h0017"><b><i>Generation of anti-CXCL9, anti-CXCL10 and anti-CXCL11 neutralizing antibodies</i></b></heading><p id="p0160" num="0160">Polyclonal antibodies (Abs) to CXCL9, CXCL10 and CXCL11 were generated as was previously described [<nplcit id="ncit0180" npl-type="s"><text>Goldberg et al., J Immunol (2004) 173:6465-6471</text></nplcit>]. Briefly, female Lewis rats were subjected to subsequent administrations (in two week intervals) of murine CXCL9, CXCL10 or CXCL11 encoding DNA plasmids as was previously described [<nplcit id="ncit0181" npl-type="s"><text>Wildbaum et al., J Immunol (2002) 168:5885-92</text></nplcit>]. Ten days after the last administration, rats were injected with 100 µg commercial recombinant gene product encoded by each vaccine (R&amp;D Systems, Minneapolis, MN) emulsified in IFA (Incomplete Freud's Adjuvant). Ten days later, anti-CXCL9, anti-CXCL10 or anti-CXCL11 antibodies were purified from sera of these rats by a two step purification: (1) IgG fraction was purified using a High-Trap Protein G column (BD Biosciences, Piscataway, NJ) and (2) cytokine-specific Abs were purified using a cyanogen bromide-activated Sepharose column, as described hereinafter. Each recombinant mouse cytokine (at a concentration of 5 mg), was bound to cyanogen bromide-activated Sepharose column according to the manufacturer's instructions (Pharmacia Biotech, Uppsala, Sweden). Each IgG fraction was loaded on the column and then eluted by an acidic elution buffer (glycine,<!-- EPO <DP n="34"> --> pH 2.5). Isotype determination of the purified Abs revealed that purified Abs were mostly of the IgG2a isotype (data not shown).</p><heading id="h0018"><b><i>Administration of anti-CXCL9, anti-CXCL10 and anti-CXCL11 neutralizing antibodies to mice</i></b></heading><p id="p0161" num="0161">Just after disease onset (day 11), EAE induced mice were separated into five groups based on the severity of the disease (6 per group). Three of these groups were subjected to intramuscular (i.m.) injections of one of the antibodies (against CXCL9, CXCL10 or CXCL11) or control antibodies from rats previously administered with an empty vector. All antibodies were administered from day 11-on every other day. One group of mice remained untreated. An observer blind to the experimental protocol then monitored the development and progression of disease.</p><heading id="h0019"><b><i>Migration Assay</i></b></heading><p id="p0162" num="0162">Cell migration assay was performed. CXCR3+ T cells from a MOGp33-55 specific encephalitogenic CD4+ T cell line were loaded in the upper chamber of a 6.5-mm diameter, 5-µm-pore polycarbonate Transwell cultureinsert (Costar, Cambridge, MA). The lower chamber contained each detected chemokine, or chemokine based Ig fusion protein, with, or without the addition of chemokine specific neutralizing antibodies. Incubation of cells was carried out at 37 °C in 7.5 % CO<sub>2</sub> for 2 hours. Migrated cells were collected and counted using a FACSCatibur (BD Biosciences). Percentage of cell migration was calculated as the number of cells that migrated to lower chamber divided by number of cells originally plated in the upper chamber.</p><heading id="h0020"><b>RESULTS</b></heading><p id="p0163" num="0163">Antibodies generated against each of the three CXCR3 ligands (CXCL9, CXCL10 and CXCL11) were first determined for their specificity. As shown in <figref idrefs="f0001">Figure1A</figref>, each antibody selectively bound its recombinant target gene product, but not each of the other CXCR3 ligands. Moreover, these antibodies did not bind numerous other chemokines that have been associated with regulation of inflammatory responses including: CCL2, CCL5 and CXCL12 (data not shown). Trans-well migration analysis was then carried out to verify antibody neutralization of the chemokines. <figref idrefs="f0001">Figure 1B</figref> shows that indeed each antibody selectively blocked chemokine-induced migration of its target chemokine (about 80 % each, p &lt; 0.001), but not migration induced by the other CXCR3 ligands.<!-- EPO <DP n="35"> --></p><p id="p0164" num="0164">Subjection of EAE induced mice to CXCL9, CXCL10 or CXCL11 antibodies differentially affected the severity of an ongoing disease as shown in <figref idrefs="f0002">Figure 2</figref>. Neutralization of CXCL10 significantly suppressed the disease (mean maximal score of 0.66 ± 0.23 compared to 2.83 ± 0.66 for control mice, p &lt; 0.001) while neutralization of CXCL9 also suppressed the disease (mean maximal score of 1.66 ± 0.35 compared to 2.83 ± 0.66 for control mice, p &lt; 0.03), but significantly less than the effect of anti CXCL10 therapy (p &lt; 0.03). In sharp contrast, administration of anti-CXCL11 antibodies aggravated the severity of the disease (mean maximal score of 4 ± 0 compared to 2.83 ± 0.66 for control mice, p &lt; 0.001), suggesting that while CXCL9 and CXCL10 function as pro-inflammatory cytokines, CXCL11 functions as a regulatory chemokine that antagonizes the pro-inflammatory activities of the other two CXCR3 ligands.</p><heading id="h0021"><b>EXAMPLE 2</b></heading><heading id="h0022"><b><i>Construction of CXCL11-Ig and CXCL10-Ig fusion proteins which maintain their functional properties</i></b></heading><p id="p0165" num="0165">Chemokines have a very short half life. Therefore, in an attempt to study the potential therapeutic competence of CXCL11, in comparison to CXCL10, recombinant fusion molecules comprising CXCL11 or CXCL 10 fused to the IgG1 heavy chain Fc were generated which maintained their functional properties.</p><heading id="h0023"><b>MATERIALS AND METHODS</b></heading><heading id="h0024"><b><i>Construction of CXCL11-IgG and CXCL10-IgG fusion proteins</i></b></heading><p id="p0166" num="0166">The nucleic acid vectors encoding CXCL11-Ig or CXCL10-Ig fusion proteins of the present invention were constructed as follows: cDNA encoding the constant region (Hinge-CH2-CH3, SEQ ID NO: 3) of human IgG1 heavy chain was generated by RT-PCR of RNA extracted from LPS and IL-4 activated peripheral blood mononuclear cells (PBMC) using the primers: sense, 5' ctcgagCCCAAATCTTGTGACAAAAC 3' (SEQ ID NO: 7) and antisense: 5' gggcccTTTACCCGGGGACAGGGAGA 3' (SEQ ID NO: 8). cDNA encoding the constant region (Hinge-CH2-CH3, SEQ ID NO: 21) of murine IgG1 heavy chain was generated by RT-PCR of RNA extracted from LPS and IL-4 activated mouse spleen cells using the primers: sense, 5' CCGCTCGAGGTGCCCAGGGATTGTGGTTG 3' (SEQ ID NO: 23) and antisense: 5' TTGTTCGGGCCCTTTACCAGGAGAGTGGGAGA 3' (SEQ ID NO: 24). PCR products were digested with XhoI and ApaI and ligated into<!-- EPO <DP n="36"> --> mammalian expression/secretion vector pSecTag2/Hygro B (Invitrogen Life Technologies, San Diego, CA).</p><p id="p0167" num="0167">cDNA encoding mouse CXCL11 (GenBank Accession No. NM_019494, SEQ ID NO: 9 was generated by RT-PCR of RNA extracted from mouse splenocytes using the primers: sense, 5' gctagc ATGAACAGGAAGGTCACAGCCATAGC 3' (SEQ ID NO: 11) and antisense, 5' ctcgagCATGTTTTGACGCCTTAAAAAATT 3' (SEQ ID NO: 12). cDNA encoding mouse CXCL10 (GenBank Accession No. NM_ NM_021274 SEQ ID NO: 15) was generated by RT-PCR of RNA extracted from mouse splenocytes using the primers: sense, 5' gctagc ATGAACCCAAGTGCTGCCGTCATTTT 3' (SEQ ID NO: 17) and antisense, 5' ctcgag AGGAGCCCTTTTAGACCT7TTTTG 3' (SEQ ID NO: 18). cDNA encoding β-actin (SEQ ID NO: 25), used as a control, was generated by RT-PCR of RNA extracted from mouse splenocytes using the primers: sense, 5' gctagc ATGGATGACGATATCGCTGCGCTGGTCGT 3' (SEQ ID NO: 27) and antisense, 5' ctcgag GAAGCACTTGCGGTGCACGATGGAG 3' (SEQ ID NO: 28). PCR products were digested with NheI and XhoI and following sequence verification, the amplified PCR products were subcloned into the pSec-Tag2 vector (Invitrogen, San Diego, CA) upstream of the mouse IgG1 fragments to create the fusion proteins: CXCL11-Ig (SEQ ID NO: 14), CXCL10-Ig (SEQ ID NO: 29) or the control peptide β-actin-Ig (SEQ ID NO: 30).</p><p id="p0168" num="0168">Since alterations in the amino acid sequence at the N-terminus of chemokines might change their properties, NheI was selected for the cloning procedure and the original murine kappa chain leader sequence found in pSecTag2/Hygro B was replaced by either mouse CXCL11-IgG leader sequence, CXCL10-IgG leader sequence, or β-actin-IgG leader sequence accordingly. The fused fragments were sequenced by dideoxynucleotide sequencing (Sequenase version 2; Upstate Biotechnology, Cleveland, OH).</p><heading id="h0025"><b><i>Expression and purification of CXCL11-IgG and CXCL10-IgG fusion proteins</i></b></heading><p id="p0169" num="0169">The pSec-CXCL11-IgG, pSec-CXCL10-IgG or pSec-β-actin-IgG plasmids were separately co-transfected into DG44 Chinese hamster ovary (CHO) cells that have a double deletion for the dihydrofolate reductase (DHFR) gene (DG44 CHO DHFR<sup>-/-</sup> cells, provided by Dr. Lawrence Chasin from Columbia University, USA, ATCC Accession No. CRL-9096), with CHO DHFR minigene vector, which transfects DHFR-deficient CHO cells with high efficiency, using jet PEI (Polypluse transfection - Illkirch Cedex, France) according the manufacturer's protocol. Stably transfected cells were selected in a culture medium (MEM-alpha) containing hygromycine (200 µg/ml) and increasing doses of<!-- EPO <DP n="37"> --> methotrixate (2.5 nM to 0.1 mM). The fusion protein was expressed as a disulphide-linked homodimer similar to IgG1, and it had a molecular weight of approximately 72 kDa consisting of two identical 36 kDa subunits. The fusion protein was purified from the culture medium by High-Trap protein G affinity column (BD Biosciences, Piscataway, NJ) and verified by Western blot analysis using mouse anti-hlg (Jackson ImmunoResearch Laboratories, West Grove, PA) as primary antibody and donkey anti-mouse HRP-conjugated antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) as secondary antibody.</p><heading id="h0026"><b>RESULTS</b></heading><p id="p0170" num="0170">Recombinant CXCL11-IgG and CXCL10-IgG fusion proteins were successfully generated, each preserving its selective target recognition pattern and its ability to attract CXCR3+ T cells in a trans-well system (<figref idrefs="f0002">Figure 3</figref>). The chemokine specific neutralizing antibodies generated according to the teachings of the present invention (see Example 1), as well as commercially available neutralizing antibodies (data not shown) could selectively neutralize the ability of each fusion protein to attract CXCR3+ T cells (<figref idrefs="f0002">Figure 3</figref>).</p><p id="p0171" num="0171">Preliminary experiments (data not shown) showed that the fusion proteins constructed with human IgG1 (Fc) or the mouse IgG1 (Fc) exerted the same biological properties, as illustrated in <figref idrefs="f0002">Figure 3</figref>. Since the in vivo experimental studies included interventions in a long-term form of ongoing EAE, inventors used the murine constructs encoding mouse IgG1.</p><heading id="h0027"><b>EXAMPLE 3</b></heading><heading id="h0028"><b><i>CXCL11-Ig fusion protein suppresses ongoing EAE by selecting IL-10 and IL-4 producing T cells</i></b></heading><p id="p0172" num="0172">Since anti-CXCL11 antibodies were shown to aggravate the severity of EAE, the present inventors hypothesized that CXCL11 antagonizes CXCL10. In order to test this hypothesis a CXCL11-Ig fusion protein was tested for its competence to suppress ongoing EAE.<!-- EPO <DP n="38"> --></p><heading id="h0029"><b>MATERIALS AND METHODS</b></heading><heading id="h0030"><b><i>Animals</i></b></heading><p id="p0173" num="0173">Mice were used as described in detail in Example 1 hereinabove.</p><heading id="h0031"><b><i>Induction of active disease</i></b></heading><p id="p0174" num="0174">Induction of active EAE was effected as described in detail in Example 1 hereinabove.</p><heading id="h0032"><b><i>Generation of CXCL11-hIg and CXCL10-hIg fusion proteins</i></b></heading><p id="p0175" num="0175">As described in detail in Example 2, hereinabove.</p><heading id="h0033"><b><i>Administration of CXCL11-Ig and CXCL10-Ig fusion proteins to EAE induced mice</i></b></heading><p id="p0176" num="0176">Just after the onset of active EAE disease (day 11), C57BL\6 female mice were separated into five groups of equally sick mice (6 per group). On days 11, 13, 15, and 17 after the induction of disease, EAE mice were subjected to i.m. injections of either CXCL10-IgG or CXCL11-IgG at a concentration of 200 µg / mouse. The remaining three groups were administered with either isotype-matched control IgG, purified β-actin-IgG or remained untreated. An observer blind to the experimental protocol then monitored the development and progression of disease.</p><heading id="h0034"><b><i>Isolation and ex-vivo activation of EAE primary T cells</i></b></heading><p id="p0177" num="0177">Spleen cells were collected from the cervical lymph nodes (CLN) of mice at the peak of disease (18 days post induction of EAE). Cells were cultured in a humidified 7.5 % CO<sub>2</sub> atmosphere at 37 °C and stimulated with 50 µg/ml MOG<sub>35-53</sub> peptide (target antigen). 10 x 10<sup>6</sup> spleen cells were cultured in 24-well plates in the presence of CXCL10-IgG, CXCL11-IgG or PBS for 72 hours. Supernatants were collected and analyzed by ELISA.</p><heading id="h0035"><b><i>ELISA</i></b></heading><p id="p0178" num="0178">Secreted levels of IL-10, IL-12, TNF-α, IFNγ, IL-2 and IL-4 were each measured by commercially available ELISA kits: IL-10, IL-2 and IFN-γ (BioLegend, San Diego, CA), IL-12 and TNF-α (Bender Medical Systems, Vienna, Austria), and IL-4 (BioLegend, San Diego, CA).</p><heading id="h0036"><b>RESULTS</b></heading><p id="p0179" num="0179">As shown in <figref idrefs="f0003">Figure 4</figref>, treatment of EAE induced mice with CXCL11-IgG rapidly suppressed disease severity (On day 20, mean EAE score of treated mice was 0.83 ± 0.33<!-- EPO <DP n="39"> --> compared to 3 ± 0.66 in control mice, p &lt; 0.001). By contrast, administration of CXCL10-IgG to EAE induced mice during an ongoing disease significantly aggravated its severity (On day 20, mean EAE score of CXCL10-IgG treated mice was 4 ± 0.5 compared to 3 ± 0.66 in control mice, p &lt; 0.01). Subjection of EAE induced mice to the control fusion protein (β-actin-IgG) had no effect on the manifestation of the disease (<figref idrefs="f0003">Figure 4</figref>).</p><p id="p0180" num="0180">Results clearly showed that treatment of EAE induced mice with CXCL10-IgG lead to a significant elevation in TNF-α secretion from primary T cells (<figref idrefs="f0004">Figure 5A</figref>, 728 ± 63 compared to 401 ± 38 pg/ml for target antigen, p &lt; 0.001). Similar results were reported for IFN-γ secretion (<figref idrefs="f0004">Figure 5B</figref>, 86.<figref idrefs="f0004">5</figref> ± 6.3 compared to 46 ± 4.6 ng/ml for target antigen, p &lt; 0.01), IL-12 secretion (<figref idrefs="f0004">Figure 5C</figref>, 325 ± 38 compared to 176 ± 62 pg/ml for target antigen, p &lt; 0.01) and IL-2 secretion (<figref idrefs="f0004">Figure 5D</figref>, 4400 ± 460 compared to 2200 ± 300 pg/ml for target antigen). In sharp contrast, successful therapy with CXCL11-IgG lead to a significant reduction in TNF-α secretion (<figref idrefs="f0004">Figure 5A</figref>, 90 ± 12 compared to 401 ± 38 pg/ml for target antigen, p &lt; 0.0001), IFN-γ secretion (<figref idrefs="f0004">Figure 5B</figref>, <figref idrefs="f0007">9</figref> ± 2 compared to 46 ± 4.6 ng/ml for target antigen, p &lt; 0.0001), and IL-12 secretion (<figref idrefs="f0004">Figure 5C</figref>, 36 ± 4 compared to 176 ± 62 pg/ml for target antigen, p &lt; 0.0001). Additionally, CXCL11-IgG treatment led to an elevated production of the immunoregulatory cytokines IL-4 (<figref idrefs="f0004">Figure 5E</figref>, 1±0.5 compared to 41 ± 6 pg/ml, p &lt; 0.0001) and IL-10 (<figref idrefs="f0004">Figure 5F</figref>, 280 ± 33 compared to 133 ± 16 pg/ml for target antigen, p &lt; 0.001).</p><heading id="h0037"><b><i>EXAMPLE 4</i></b></heading><heading id="h0038"><b><i>Antigen-specific T cells from protected donors suppress active EAE in adoptive transfer experiments</i></b></heading><p id="p0181" num="0181">In an attempt to elucidate whether CXCL11 selects antigen specific regulatory T cells (T-reg), T cells from EAE induced donor mice treated with CXCL11-IgG, were selectively transferred to EAE induced recipient mice.</p><heading id="h0039"><b>MATERIALS AND METHODS</b></heading><heading id="h0040"><b><i>Animals</i></b></heading><p id="p0182" num="0182">Mice were used as described in detail in Example 1 hereinabove.<!-- EPO <DP n="40"> --></p><heading id="h0041"><b><i>Induction of active disease</i></b></heading><p id="p0183" num="0183">Induction of active EAE was effected as described in detail in Example 1 hereinabove.</p><heading id="h0042"><b><i>Generation of CXCL11-hIg fusion protein</i></b></heading><p id="p0184" num="0184">As described in detail in Example 2, hereinabove.</p><heading id="h0043"><b><i>Administration of CXCLII-Ig fusion protein to EAE induced mice</i></b></heading><p id="p0185" num="0185">As described in detail in Example 3, hereinabove.</p><heading id="h0044"><b><i>Generation of spleen cells from donor mice and adoptive transfer to recipient EAE induced mice</i></b></heading><p id="p0186" num="0186">Primary spleen cells from CXCL11-IgG treated or untreated EAE induced donor mice were collected from mice 15 days post induction of EAE. Cells were cultured in a humidified 7.5 % CO<sub>2</sub> atmosphere at 37 °C and stimulated with their target autoimmune antigen, MOG<sub>35-53</sub> peptide, at a concentration of 50 µg/ml for 3 days. These cells were then administered (30 x 10<sup>6</sup>/ mouse) to EAE induced recipient mice, just after the onset of disease (on day 11).</p><heading id="h0045"><b>RESULTS</b></heading><p id="p0187" num="0187">As evident from the results (<figref idrefs="f0005">Figure 6</figref>), administration of T cells from CXCL11-IgG treated donor mice to EAE induced recipient mice lead to a fast remission of active EAE disease (on day 25, mean EAE score recorded was 0.5 ± 0.3 compared to 2.66 ± 0.3 for control mice, p &lt; 0.001). Conversely, administration of T cells from untreated EAE induced mice during ongoing disease significantly aggravated its severity (On day 25, mean EAE score recorded was 4 ± 0.5 compared to 2.66 ± 0.3 for control mice, p &lt; 0.005).</p><heading id="h0046"><b><i>EXAMPLE 5</i></b></heading><heading id="h0047"><b><i>CXCL11 redirects the polarization of antigen specific effector-inflammatory T cells</i></b></heading><p id="p0188" num="0188">During the accelerating phase of disease in MOGp33-55/CFA induced EAE, the vast majority of MOGp33-55 CD4+ specific T cells display the IFN-γ<sup>high</sup> IL-4<sup>low</sup> IL-10<sup>low</sup> effector phenotype [<nplcit id="ncit0182" npl-type="s"><text>Goldberg et al., J Immunol (2004) 173:6465-6471</text></nplcit>]. Therefore, an attempt was made to determine whether CXCL11 redirects the polarization of these antigen specific T cells into IFN-γ<sup>low</sup> IL-4<sup>high</sup> and/or IFN-γ<sup>low</sup> IL-10<sup>high</sup> T-reg cells.<!-- EPO <DP n="41"> --></p><heading id="h0048"><b>MATERIALS AND METHODS</b></heading><heading id="h0049"><b><i>Animals</i></b></heading><p id="p0189" num="0189">Mice were used as described in detail in Example 1 hereinabove.</p><heading id="h0050"><b><i>Induction of active disease</i></b></heading><p id="p0190" num="0190">Induction of active EAE was effected as described in detail in Example 1 hereinabove.</p><heading id="h0051"><b><i>Generation of CXCL11-hIg fusion protein</i></b></heading><p id="p0191" num="0191">As described in detail in Example 2, hereinabove.</p><heading id="h0052"><b><i>Generation of Spleen cells</i></b></heading><p id="p0192" num="0192">Primary spleen cells were isolated from EAE induced mice (2 days after the onset of disease). Cells were cultured in a humidified 7.5 % CO<sub>2</sub> atmosphere at 37 °C and stimulated with their target autoimmune antigen, MOG<sub>35-53</sub> peptide, at a concentration of 50 µg/ml. Cultures were or were not additionally supplemented with CXCL11-IgG at a concentration of 20 µg/ml.</p><heading id="h0053"><b><i>Flow cytometry analysis</i></b></heading><p id="p0193" num="0193">Flow cytometry analysis was conducted according to the protocol previously described by Schif-Zuck et al. [<nplcit id="ncit0183" npl-type="s"><text>Schif-Zuck et al., J Immunol (2005) 174:4307-4315</text></nplcit>]. Briefly, 10<sup>6</sup> cells were suspended in 1000 µl dyeing buffer containing an anti CD4-APC (BioLegend, San Diego, CA) labeled for 5 minutes on ice. The cells were washed three times in dyeing buffer and resuspended in 100 µl 1 % PFA and transfered into FACS tubes.</p><p id="p0194" num="0194">Intracellular staining of IL-10 was conducted using PE labeled anti-mouse IL-10 (BD Biosciences).</p><heading id="h0054"><b>RESULTS</b></heading><p id="p0195" num="0195"><figref idrefs="f0006">Figures 7A-E</figref> clearly show that in the presence of CXCL11-IgG, antigen specific T cells redirect their polarization into high IL-10, high IL-4, low IFN-γ producing T cells (<figref idrefs="f0006">Figures 7A, 7B and 7C</figref>, respectively). These cells also produce significantly reduced levels of the pro-inflammatory cytokine TNF-α (<figref idrefs="f0006">Figure 7D</figref>, 178 ± 32 compared to 460 ± 65 pg/ml for untreated T cells, p &lt; 0.001). No significant change was observed in TGF-β production (<figref idrefs="f0006">Figure 7E</figref>). Additionally, supplementation of primary T cells with control IgG or β-actin-IgG did not lead to a significant change in cytokine production (data not shown).<!-- EPO <DP n="42"> --></p><p id="p0196" num="0196">Flow cytometry analysis (<figref idrefs="f0006">Figures 8A and 8B</figref>) revealed that only about 2 % of CD4+ control T cells (not supplemented with CXCL11-IgG) were polarized into a high IL-10 producing CD4+ T cells. Conversely, MOGp33-55 specific activation in the presence of CXCL11-IgG resulted in a massive skewing into high IL-10 producing CD4+ T cells (42 %). Further analysis of these cells revealed that they were CD4<sup>+</sup>CD25<sup>-</sup> FOXp3<sup>-</sup> T cells (data not shown).</p><heading id="h0055"><b><i>EXAMPLE 6</i></b></heading><heading id="h0056"><b><i>Primary T cells stimulated ex-vivo with CXL11-IgG suppress active EAE in adoptive transfer experiments</i></b></heading><p id="p0197" num="0197">In an attempt to reveal the therapeutic competence on EAE of IFN-γ<sup>low</sup> IL-4 <sup>high</sup> IL-10<sup>high</sup> T-reg cells (generated following stimulation of primary spleen cells with CXCL11-IgG), adoptive transfer experiments were carried out.</p><heading id="h0057"><b>MATERIALS AND METHODS</b></heading><heading id="h0058"><b><i>Animals</i></b></heading><p id="p0198" num="0198">Mice were used as described in detail in Example 1 hereinabove.</p><heading id="h0059"><b><i>Induction of active disease</i></b></heading><p id="p0199" num="0199">Induction of active EAE was effected as described in detail in Example 1 hereinabove.</p><heading id="h0060"><b><i>Generation of CXCL11-hIg fusion protein</i></b></heading><p id="p0200" num="0200">As described in detail in Example 2, hereinabove.</p><heading id="h0061"><b><i>Generation of Spleen cells</i></b></heading><p id="p0201" num="0201">Primary spleen cells were isolated from EAE induced mice (2 days after the onset of disease). Cells were cultured in a humidified 7.5 % CO<sub>2</sub> atmosphere at 37°C and stimulated with their target autoimmune antigen, MOG<sub>35-53</sub> peptide, at a concentration of 50 µg/ml. In addition, some of the cultures were supplemented with CXCL11-IgG at a concentration of 20 µg/ml.</p><heading id="h0062"><b><i>Adoptive transfer of primary splenocytes to recipient EAE induced mice</i></b></heading><p id="p0202" num="0202">The cultured primary T cells described hereinabove were administered (30 x 10<sup>6</sup> / mouse) to EAE induced recipient mice, just after the onset of disease (on day 11). An<!-- EPO <DP n="43"> --> additional group of mice received cells previously cultured with CXCL11-IgG followed by repeated (every 3 days) administrations of anti-IL-10 neutralizing antibodies (100 µg/mouse, R&amp;D). This group was monitored for only 10 days to avoid production of xerographic antibodies.</p><heading id="h0063"><b>RESULTS</b></heading><p id="p0203" num="0203">As depicted in <figref idrefs="f0007">Figure 9</figref>, the present inventors showed that administration of control primary T cells (which were cultured in the absence of CXCL 11-IgG) aggravated disease severity (on day 15, mean maximal score recorded was 3.8 ± 0.5 compared to 3.2 ± 0.66 for untreated EAE mice, p &lt; 0.05), while administration of IL-10 producing T cells selected in the presence of CXCL11-IgG lead to a rapid recovery of active EAE (on day 18 mean maximal score recorded was 0.5 ± 0.166 compared to 3.2 ± 0.66 for untreated EAE mice, p &lt; 0.001). Importantly, repeated administrations of anti-IL-10 antibodies reversed the therapeutic effect of these cells (on day 18 mean maximal score recorded was 28 ± 0.6 compared to 3 ± 0.66 for untreated EAE mice). The very same pattern of results were obtained when primary T cells were cultured with commercially available CXCL 11 (R&amp;D) showing that these functional activities of CXCL11 are not dependent on its stabilization as a fusion protein (data not shown).</p><heading id="h0064"><b><i>EXAMPLE 7</i></b></heading><heading id="h0065"><b><i>CXCL11 redirects the polarization of mouse and human, naive and effector T cells into IL-10 producing T regulatory cells</i></b></heading><heading id="h0066"><b>MATERIALS AND METHODS</b></heading><heading id="h0067"><b><i>Animals</i></b></heading><p id="p0204" num="0204">Mice were used as described in detail in Example 1 hereinabove.</p><heading id="h0068"><b><i>Induction of active disease</i></b></heading><p id="p0205" num="0205">Induction of active EAE was effected as described in detail in Example 1 hereinabove.</p><heading id="h0069"><b><i>Generation: of Spleen cells</i></b></heading><p id="p0206" num="0206">Primary spleen cells were isolated from EAE induced C57BL/6 mice (day 9).<!-- EPO <DP n="44"> --></p><p id="p0207" num="0207">Cells (10<sup>6</sup> cells/ml) were cultured in a humidified 7.5 % CO<sub>2</sub> atmosphere at 37 °C for 72 hours and stimulated with their target autoimmune antigen, MOG<sub>35-53</sub> peptide, at a concentration of 50 µg/ml. In addition, the cultures were supplemented with either recombinant mCXCL10 (R&amp;D) or mCXCL11 (R&amp;D) at a concentration of 50 ng/ml.</p><heading id="h0070"><b><i>Isolation of naïve CD4+ T cells</i></b></heading><p id="p0208" num="0208">Naïve CD4+ T cells were purified from naïve C57BL/6 mice spleens using magnetic beads and were stimulated (300,000 cell/ml) for 48 hours with immobilized anti-CD3ε mAb (2 µg/ml, Biolegend) and soluble anti-CD28 mAb (2 µg/ml, Biolegend) in the presence of either rmCXCL10 (R&amp;D) or rmCXCL11 (R&amp;D) at a concentration of 50 ng/ml.</p><heading id="h0071"><b><i>Human T cells</i></b></heading><p id="p0209" num="0209">Human CD4+ T cells were purified from peripheral blood mononuclear cells using anti-CD4 magnetic beads (MACS beads, according the manufacturer protocol) and were stimulated (300,000 cell/ml) for 48 hours with anti-CD3ε mAb (2 µg/ml, Biolegend) and soluble anti-CD28 mAb (2 µg/ml, Biolegend) in the presence of 10 ng/ml rhCXCL10 (R&amp;D) or rhCXCL11 (R&amp;D) with or without 0.5 µg/ml of neutralizing anti-CXCR3 antibody (R&amp;D).</p><heading id="h0072"><b><i>ELISA</i></b></heading><p id="p0210" num="0210">As described in detail in Example 3, hereinabove.</p><heading id="h0073"><b>RESULTS</b></heading><p id="p0211" num="0211">As shown in <figref idrefs="f0009">Figures 10G-K</figref>, CXCL11 directly re-polarizes naïve CD4+ T cells undergoing T-cell activation into IL-10 producing regulatory T cells. These results presented a very similar pattern of cytokine secretion as were seen with effector T cells from EAE mice which were activated in vitro by their target antigen in the presence of antigen presenting cells (<figref idrefs="f0008">Figures 10A-F</figref> and example 5 hereinabove). Similar results were also illustrated with purified human CD4+ cells activated under similar conditions (<figref idrefs="f0010">Figure 11</figref>). It should be noted that mouse and human rCXCL11 were not cross-reactive (results not shown).<!-- EPO <DP n="45"> --></p><heading id="h0074"><b><i>EXAMPLE 8</i></b></heading><heading id="h0075"><b><i>CXL11 redirects the polarization of human T cells in a CXCR3 dependent manner</i></b></heading><p id="p0212" num="0212">In an attempt to elucidate how CXCL11 redirects the polarization of T cells into high IL-10, high IL-4, low IFN-γ producing T cells, experiments utilizing anti-CXCR3 antibodies were carried out.</p><heading id="h0076"><b>MATERIALS AND METHODS</b></heading><heading id="h0077"><b><i>Human T cells</i></b></heading><p id="p0213" num="0213">As described in detail in Example 7, hereinabove.</p><heading id="h0078"><b><i>ELISA</i></b></heading><p id="p0214" num="0214">As described in detail in Example 3, hereinabove.</p><heading id="h0079"><b>RESULTS</b></heading><p id="p0215" num="0215">CXCL11 binds two different receptors, CXCR3 and CXCR7, yet it induces migration only via CXCR3 [<nplcit id="ncit0184" npl-type="s"><text>Burns et al., J Exp Med (2006) 203: 2201-13</text></nplcit>]. To elucidate the role CXCR3 plays in CXCL11 induced migration and re-pularization of T cells, an anti-CXCR3 blocking was used. First, dose dependent experiments were carried out to determine the in vitro concentration of antibody required for total blockage of CXCL11 induced migration (data not shown). Under those conditions, experiment were carried out to illustrate the contribution of CXCR3 to CXCL11 induced polarization of CD4+ T cells. As clearly shown in <figref idrefs="f0010">Figure 11</figref>, the use of anti-CXCR3 antibody blocked IL-10 production of T cells by approximately 75 %, implicating the pivotal role of CXCR3 in CXCL11 repolarization ofT cells.</p><p id="p0216" num="0216">It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a singe embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.<!-- EPO <DP n="46"> --></p><heading id="h0080">SEQUENCE LISTING</heading><p id="p0217" num="0217"><ul><li>&lt;110&gt; Rappaport Family Institute for Research in the Medical Sciences<br/>
Karin, Nathan<br/>
Zohar, Yaniv<br/>
wildbaum, Gizi</li><li>&lt;120&gt; AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND METHODS OF USING SAME</li><li>&lt;130&gt; 43435</li><li>&lt;160&gt; 31</li><li>&lt;170&gt; PatentIn version 3.4</li><li>&lt;210&gt; 1<br/>
&lt;211&gt; 285<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Homo sapiens</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;223&gt; Human CXCL11</li><li>&lt;400&gt; 1
<img id="ib0001" file="imgb0001.tif" wi="128" he="29" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 2<br/>
&lt;211&gt; 94<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Homo sapiens</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;223&gt; Human CXCL11</li><li>&lt;400&gt; 2
<img id="ib0002" file="imgb0002.tif" wi="112" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 3<br/>
&lt;211&gt; 714<br/>
<!-- EPO <DP n="47"> -->&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; human Ig derived fragment coding sequence</li><li>&lt;400&gt; 3
<img id="ib0003" file="imgb0003.tif" wi="128" he="73" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 4<br/>
&lt;211&gt; 238<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; human Ig derived fragment</li><li>&lt;400&gt; 4
<img id="ib0004" file="imgb0004.tif" wi="117" he="108" img-content="dna" img-format="tif"/><!-- EPO <DP n="48"> -->
<img id="ib0005" file="imgb0005.tif" wi="115" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 5<br/>
&lt;211&gt; 996<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Human CXCL11-Ig fusion protein coding sequence</li><li>&lt;400&gt; 5
<img id="ib0006" file="imgb0006.tif" wi="127" he="104" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 6<br/>
&lt;211&gt; 332<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
<!-- EPO <DP n="49"> -->&lt;223&gt; Human CXCL11-Ig fusion protein</li><li>&lt;400&gt; 6
<img id="ib0007" file="imgb0007.tif" wi="121" he="225" img-content="dna" img-format="tif"/><!-- EPO <DP n="50"> -->
<img id="ib0008" file="imgb0008.tif" wi="112" he="32" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 7<br/>
&lt;211&gt; 26<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 7<br/>
ctcgagccca aatcttgtga caaaac    26</li><li>&lt;210&gt; 8<br/>
&lt;211&gt; 26<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 8<br/>
gggcccttta cccggggaca gggaga    26</li><li>&lt;210&gt; 9<br/>
&lt;211&gt; 303<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Mus musculus</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc feature<br/>
&lt;223&gt; Murine CXCL11</li><li>&lt;400&gt; 9
<img id="ib0009" file="imgb0009.tif" wi="129" he="35" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 10<br/>
&lt;211&gt; 94<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Mus musculus</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;223&gt; Murine CXCL11</li><li>&lt;400&gt; 10
<img id="ib0010" file="imgb0010.tif" wi="112" he="7" img-content="dna" img-format="tif"/><!-- EPO <DP n="51"> -->
<img id="ib0011" file="imgb0011.tif" wi="116" he="57" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 11<br/>
&lt;211&gt; 32<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 11<br/>
gctagcatga acaggaaggt cacagccata gc    32</li><li>&lt;210&gt; 12<br/>
&lt;211&gt; 30<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 12<br/>
ctcgagcatg ttttgacgcc ttaaaaaatt    30</li><li>&lt;210&gt; 13<br/>
&lt;211&gt; 1002<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine CXCL11-Ig fusion coding sequence</li><li>&lt;900&gt; 13
<img id="ib0012" file="imgb0012.tif" wi="127" he="73" img-content="dna" img-format="tif"/><!-- EPO <DP n="52"> -->
<img id="ib0013" file="imgb0013.tif" wi="131" he="29" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 14<br/>
&lt;211&gt; 334<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine CXCL11-Ig fusion protein</li><li>&lt;400&gt; 14
<img id="ib0014" file="imgb0014.tif" wi="115" he="171" img-content="dna" img-format="tif"/><!-- EPO <DP n="53"> -->
<img id="ib0015" file="imgb0015.tif" wi="116" he="83" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 15<br/>
&lt;211&gt; 297<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Mus musculus</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;223&gt; CXCL10</li><li>&lt;400&gt; 15
<img id="ib0016" file="imgb0016.tif" wi="128" he="29" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 16<br/>
&lt;211&gt; 98<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Mus musculus</li><li>&lt;220&gt;<br/>
&lt;221&gt; misc_feature<br/>
&lt;223&gt; CXCL10</li><li>&lt;400&gt; 16
<img id="ib0017" file="imgb0017.tif" wi="112" he="32" img-content="dna" img-format="tif"/><!-- EPO <DP n="54"> -->
<img id="ib0018" file="imgb0018.tif" wi="112" he="48" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 17<br/>
&lt;211&gt; 32<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 17<br/>
gctagcatga acccaagtgc tgccgtcatt tt    32</li><li>&lt;210&gt; 18<br/>
&lt;211&gt; 30<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 18<br/>
ctcgagagga gcccttttag accttttttg    30</li><li>&lt;210&gt; 19<br/>
&lt;211&gt; 1008<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine CXCL10-Ig fusion coding sequence</li><li>&lt;400&gt; 19
<img id="ib0019" file="imgb0019.tif" wi="128" he="86" img-content="dna" img-format="tif"/><!-- EPO <DP n="55"> -->
<img id="ib0020" file="imgb0020.tif" wi="127" he="17" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 20<br/>
&lt;211&gt; 336<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine CXCL10-Ig fusion protein</li><li>&lt;400&gt; 20
<img id="ib0021" file="imgb0021.tif" wi="120" he="183" img-content="dna" img-format="tif"/><!-- EPO <DP n="56"> -->
<img id="ib0022" file="imgb0022.tif" wi="112" he="70" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 21<br/>
&lt;211&gt; 702<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine Ig derived fragment coding sequence</li><li>&lt;400&gt; 21
<img id="ib0023" file="imgb0023.tif" wi="128" he="73" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 22<br/>
&lt;211&gt; 234<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine Ig derived fragment</li><li>&lt;400&gt; 22
<img id="ib0024" file="imgb0024.tif" wi="112" he="19" img-content="dna" img-format="tif"/><!-- EPO <DP n="57"> -->
<img id="ib0025" file="imgb0025.tif" wi="118" he="158" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 23<br/>
&lt;211&gt; 29<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt; .<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 23<br/>
ccgctcgagg tgcccaggga ttgtggttg    29</li><li>&lt;210&gt; 24<br/>
&lt;211&gt; 32<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 24<br/>
ttgttcgggc cctttaccag gagagtggga ga    32<!-- EPO <DP n="58"> --></li><li>&lt;210&gt; 25<br/>
&lt;211&gt; 2739<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Mus musculus</li><li>&lt;400&gt; 25
<img id="ib0026" file="imgb0026.tif" wi="129" he="213" img-content="dna" img-format="tif"/><!-- EPO <DP n="59"> -->
<img id="ib0027" file="imgb0027.tif" wi="130" he="73" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 26<br/>
&lt;211&gt; 912<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Mus musculus</li><li>&lt;400&gt; 26
<img id="ib0028" file="imgb0028.tif" wi="118" he="141" img-content="dna" img-format="tif"/><!-- EPO <DP n="60"> -->
<img id="ib0029" file="imgb0029.tif" wi="119" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="61"> -->
<img id="ib0030" file="imgb0030.tif" wi="115" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="62"> -->
<img id="ib0031" file="imgb0031.tif" wi="112" he="95" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 27<br/>
&lt;211&gt; 35<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 27<br/>
gctagcatgg atgacgatat cgctgcgctg gtcgt    35</li><li>&lt;210&gt; 28<br/>
&lt;211&gt; 31<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Single strand DNA oligonucleotide</li><li>&lt;400&gt; 28<br/>
ctcgaggaag cacttgcggt gcacgatgga g    31</li><li>&lt;210&gt; 29<br/>
&lt;211&gt; 3438<br/>
&lt;212&gt; DNA<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine Beta-Actin-Ig fusion protein coding sequence</li><li>&lt;400&gt; 29
<img id="ib0032" file="imgb0032.tif" wi="128" he="36" img-content="dna" img-format="tif"/><!-- EPO <DP n="63"> -->
<img id="ib0033" file="imgb0033.tif" wi="133" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="64"> -->
<img id="ib0034" file="imgb0034.tif" wi="127" he="86" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 30<br/>
&lt;211&gt; 1146<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Murine Beta-Actin-Ig fusion protein</li><li>&lt;400&gt; 30
<img id="ib0035" file="imgb0035.tif" wi="112" he="107" img-content="dna" img-format="tif"/><!-- EPO <DP n="65"> -->
<img id="ib0036" file="imgb0036.tif" wi="123" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="66"> -->
<img id="ib0037" file="imgb0037.tif" wi="119" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="67"> -->
<img id="ib0038" file="imgb0038.tif" wi="123" he="233" img-content="dna" img-format="tif"/><!-- EPO <DP n="68"> -->
<img id="ib0039" file="imgb0039.tif" wi="110" he="86" img-content="dna" img-format="tif"/></li><li>&lt;210&gt; 31<br/>
&lt;211&gt; 21<br/>
&lt;212&gt; PRT<br/>
&lt;213&gt; Artificial sequence</li><li>&lt;220&gt;<br/>
&lt;223&gt; Myelin oligodendrocyte glycoprotein peptide (MOG)p35-55</li><li>&lt;400&gt; 31
<img id="ib0040" file="imgb0040.tif" wi="112" he="19" img-content="dna" img-format="tif"/></li></ul></p></description><claims mxw-id="PCLM56984801" lang="DE" load-source="patent-office"><!-- EPO <DP n="72"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verwendung von CXCL11 gemäss SEQ ID NO:2, wie unter GenBank-Hinterlegungs-Nr. AAH05292 definiert, zur Herstellung eines Medikaments zur Behandlung einer Autoimmunkrankheit.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verwendung von T-Zellen, die ex vivo mit CXCL11 gemäss SEQ ID NO:2, wie unter GenBank-Hinterlegungs-Nr. AAH05292 definiert, zur Herstellung eines Medikaments zur Behandlung einer Autoimmunkrankheit.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verwendung nach Anspruch 2, wobei es sich bei den T-Zellen um CD4+-T-Zellen handelt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Fertigungsartikel, umfassend CXCL11 gemäss SEQ ID NO:2, wie unter GenBank-Hinterlegungs-Nr. AAH05292 definiert, und ein Anti-Multiple-Sklerose-Mittel, in einem Verpackungsmaterial verpackt und in Druckform gekennzeichnet, in oder auf dem Verpackungsmaterial, zur Verwendung bei der Behandlung von Multipler Sklerose.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Isoliertes Polypeptid, umfassend eine Aminosäuresequenz, wie in SEQ ID Nr. 6 definiert.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Pharmazeutische Zusammensetzung, umfassend das isolierte Polypeptid nach Anspruch 5 als Wirkstoff und einen pharmazeutisch akzeptablen Träger.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verwendung oder Fertigungsartikel nach Anspruch 1, 2 oder 4, wobei das CXCL11 in der Lage ist, die Sekretion von IL-10 und/oder IL-4 aus Makrophagen und T-Zellen hochzuregulieren.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verwendung oder Fertigungsartikel nach Anspruch 1, 2 oder 4, wobei das CXCL11 in der Lage ist, die Sekretion eines Cytokins aus Makrophagen und T-Zellen herunterzuregulieren, wobei das Cytokin aus der Gruppe bestehend aus TNF-α, INF-γ, IL-2 und IL-12 ausgewählt ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verwendung nach Anspruch 1 oder 2, wobei die Autoimmunkrankheit aus der Gruppe bestehend aus rheumatoider Arthritis, rheumatoider Spondylitis, Osteoarthritis, Gichtarthritis, arthritischen Zuständen, entzündeten Gelenken, Ekzemen, entzündlichen Hautzuständen, entzündlichen Augenzuständen, Konjunktivitis, Pyrese, entzündungsbedingter Gewebenekrose, Gewebeabstoß nach einer Transplantation, Morbus Crohn und ulcerativer Kolitis, Atemwegsentzündung, Asthma, Bronchitis, systemischem Lupus erythematodes, Multipler Sklerose, Myastenia gravis, progressiver systemischer Sklerose, atopischer Dermatitis, Hyperimmunoglobin E, Hepatitis-B-Antigen-negative chronische aktive Hepatitis, Hashimoto-Thyroiditis, familärem Mittelmeer-Fieber, Morbus Basedow, autoimmuner hämolytischer Anämie, primärer biliärer Zirrhose, entzündlicher<!-- EPO <DP n="73"> --> Darmkrankheit, Pemphigus vulgaris, Graft-versus-Host-Krankheit, Diabetes, Diabetes Typ I, Wegener-Granulomatose, Glomerulonephritis, Marburg-Multiple Sklerose, viraler Infektion, HIV-Infektionen und AIDS ausgewählt ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verwendung nach Anspruch 1 oder 2, wobei es sich bei der Autoimmunkrankheit um Multiple Sklerose handelt.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verwendung oder Fertigungsartikel nach Anspruch 1, 2 oder 4, wobei eine Aminosäuresequenz des CXLC11 an eine heterologe Aminosäuresequenz angehaftet ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verwendung oder Fertigungsartikel nach Anspruch 11, wobei das CXCL11, das an die heterologe Aminosäuresequenz angehaftet ist, in SEQ ID Nr. 6 definiert ist.</claim-text></claim></claims><claims mxw-id="PCLM56984802" lang="EN" load-source="patent-office"><!-- EPO <DP n="69"> --><!-- EPO <DP n="70"> --><claim id="c-en-01-0001" num="0001"><claim-text>Use of CXCL11 according to SEQ ID NO: 2 as set forth in GenBank Accession No. AAH05292 for the manufacture of a medicament for treating an autoimmune disease.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>Use of T cells ex vivo cultured with CXCL11 according to SEQ ID NO: 2 as set forth in GenBank Accession No. AAH05292 for the manufacture of a medicament for treating an autoimmune disease.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The use of claim 2, wherein said T cells are CD4+ T cells.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>An article of manufacture comprising CXCL11 according to SEQ ID NO: 2 as set forth inGenBank Accession No. AAH05292 and an anti-Multiple Sclerosis agent being packaged in a packaging material and in print, in or on said packaging material for use in the treatment of Multiple Sclerosis.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>An isolated polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 6.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A pharmaceutical composition comprising as an active ingredient the isolated polypeptide of claim 5 and a pharmaceutically acceptable carrier.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The use or article of manufacture of claim 1, 2, or 4, wherein said CXCL11 is capable of up-regulating secretion of IL-10 and/or IL-4 from macrophages and T cells.<!-- EPO <DP n="71"> --></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The use or article of manufacture of claim 1, 2, or 4, wherein said CXCL11 is capable of down-regulating secretion of a cytokine from macrophages and T cells, wherein said cytokine is selected from the group consisting of TNF-α, IFN-γ, IL-2 and IL-12.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The use of claim 1 or 2, wherein said autoimmune disease is selected from the group consisting of rheumatoid arthritis, rheumatoid spondylitis, osteroarthritis, gouty arthritis, arthritic conditions, inflamed joints, eczema, inflammatory skin conditions, inflammatory eye conditions, conjunctivitis, pyresis, tissue necrosis resulting from inflammation, tissue rejection following transplant surgery, Crohn's disease and ulcerative colitis, airway inflammation, asthma, bronchitis, systemic lupus erythematosis, multiple sclerosis, myasthenia gravis, progressive systemic sclerosis, atopic dermatitis, hyperimmunoglobin E, hepatitis B antigen negative chronic active hepatitis, Hashimoto's thyroiditis, familial Mediterranean fever, Grave's disease, autoimmune haemolytic anemia, primary biliary cirrhosis, inflammatory bowel disease, pemphigus vulgaris, graft versus host disease, diabetes, Type I diabetes, Wegener's granulomatosis, glomerulonephritis, Marburg multiple sclerosis, viral infections, HIV infections and AIDS.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The use of claim 1 or 2, wherein said autoimmune disease is Multiple Sclerosis.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The use or article of manufacture of claim 1, 2 or 4, wherein an amino acid sequence of said CXCL11 is attached to a heterologous amino acid sequence.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The use or article of manufacture of claim 11, wherein said CXCL11 attached to said heterologous amino acid sequence is set forth in SEQ ID NO: 6.</claim-text></claim></claims><claims mxw-id="PCLM56984803" lang="FR" load-source="patent-office"><!-- EPO <DP n="74"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Utilisation de CXCL11 selon SEQ ID NO:2 tel que décrit dans le N° d'accès GenBank AAH05292 pour la fabrication d'un médicament destiné au traitement d'une maladie auto-immune.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Utilisation de cellules T cultivées <i>ex vivo</i> avec CXCL11 selon SEQ ID NO:2 tel que décrit dans le N° d'accès GenBank AAH05292 pour la fabrication d'un médicament destiné au traitement d'une maladie auto-immune.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Utilisation selon la revendication 2, dans laquelle lesdites cellules T sont des cellules T CD4+.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Article de manufacture comprenant CXCL11 selon SEQ ID NO:2 tel que décrit dans le N° d'accès GenBank AAH05292 et un agent anti-sclérose en plaques, qui est conditionné dans un matériau de conditionnement et est identifié par impression, dans ou sur ledit matériau de conditionnement, et destiné à être utilisé dans le traitement de la sclérose en plaques.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Polypeptide isolé comprenant une séquence d'acides aminés telle que décrite dans SEQ ID NO: 6.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composition pharmaceutique comprenant, en tant qu'ingrédient actif, le polypeptide isolé selon la revendication 5 et un véhicule pharmaceutiquement acceptable.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Utilisation ou article de manufacture selon la revendication 1, 2, ou 4, où ledit CXCL11 est capable de<!-- EPO <DP n="75"> --> positivement réguler la sécrétion d'IL-10 et/ou d'IL-4 à partir de macrophages et de cellules T.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Utilisation ou article de manufacture selon la revendication 1, 2, ou 4, où ledit CXCL11 est capable de négativement réguler la sécrétion d'une cytokine à partir de macrophages et de cellules T, où ladite cytokine est sélectionnée dans le groupe consistant en le TNF-α, l'IFN-γ, l'IL-2 et l'IL-12.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Utilisation selon la revendication 1 ou 2, dans laquelle ladite maladie auto-immune est sélectionnée dans le groupe consistant en la polyarthrite rhumatoïde, la spondylarthrite rhumatoïde, l'ostéoarthrite, l'arthrite goutteuse, des pathologies arthritiques, une inflammation des articulations, l'eczéma, des pathologies cutanées inflammatoires, des pathologies oculaires inflammatoires, la conjonctivite, la pyrexie, une nécrose tissulaire résultant d'une inflammation, un rejet tissulaire suite à une chirurgie de greffe, la maladie de Crohn et la colite ulcéreuse, une inflammation des voies aériennes, l'asthme, la bronchite, le lupus érythémateux systémique, la sclérose en plaques, la myasthénie grave, la sclérose systémique progressive, la dermatite atopique, l'hyperimmunoglobulinémie E, une hépatite chronique active négative pour l'antigène de l'hépatite B, la thyroïdite de Hashimoto, la fièvre méditerranéenne familiale, la maladie de Graves, une anémie hémolytique auto-immune, la cirrhose biliaire primitive, une maladie intestinale inflammatoire, le pemphigus vulgaire, la maladie du greffon contre l'hôte, le diabète, le diabète de type I, la granulomatose de Wegener, une glomérulonéphrite, la sclérose en plaques de Marburg, des infections virales, des infections par le VIH et le SIDA.<!-- EPO <DP n="76"> --></claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Utilisation selon la revendication 1 ou 2, dans laquelle ladite maladie auto-immune est la sclérose en plaques.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Utilisation ou article de manufacture selon la revendication 1, 2 ou 4, où une séquence d'acides aminés dudit CXCL11 est attachée à une séquence d'acides aminés hétérologue.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Utilisation ou article de manufacture selon la revendication 11, où ledit CXCL11 attaché à ladite séquence d'acides aminés hétérologue est décrit dans SEQ ID NO: 6.</claim-text></claim></claims><drawings mxw-id="PDW16671963" load-source="patent-office"><!-- EPO <DP n="77"> --><figure id="f0001" num="1a,1b"><img id="if0001" file="imgf0001.tif" wi="109" he="221" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="78"> --><figure id="f0002" num="2,3"><img id="if0002" file="imgf0002.tif" wi="142" he="229" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="79"> --><figure id="f0003" num="4"><img id="if0003" file="imgf0003.tif" wi="135" he="126" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="80"> --><figure id="f0004" num="5a,5b,5c,5d,5e,5f"><img id="if0004" file="imgf0004.tif" wi="165" he="210" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="81"> --><figure id="f0005" num="6"><img id="if0005" file="imgf0005.tif" wi="131" he="115" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="82"> --><figure id="f0006" num="7a,7b,7c,7d,7e,8a,8b"><img id="if0006" file="imgf0006.tif" wi="161" he="231" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="83"> --><figure id="f0007" num="9"><img id="if0007" file="imgf0007.tif" wi="133" he="117" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="84"> --><figure id="f0008" num="10a,10b,10c,10d,10e,10f"><img id="if0008" file="imgf0008.tif" wi="165" he="223" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="85"> --><figure id="f0009" num="10g,10h,10i,10j,10k"><img id="if0009" file="imgf0009.tif" wi="165" he="219" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="86"> --><figure id="f0010" num="11"><img id="if0010" file="imgf0010.tif" wi="160" he="204" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
